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ABSTRACT
Objective
The use of a low molecular weight heparin, enoxaparin was evaluated in the 
prevention and treatment o f deep vein thrombosis. Patterns o f use were analysed 
and measured against pre-determined criteria with a view to promoting optimal use 
and identifying those factors, which may contribute to safer use o f the drug.
Methods
A 12 week prospective descriptive study was carried out in a patient population of 
76 patients, comprising 26% orthopaedic, 22% vascular, 17% gynaecological and 
35% medical patients admitted to the Johannesburg General Hospital. A data 
collection sheet was used to record the relevant data from the patients’ medical 
records and further analysed using Microsoft Excel 1997.
Results
Ninety-two percent of hip replacement patients received the correct prophylactic 
dose of 40mg daily and 88% received the correct duration of therapy of between 7 
to 10 days. In the prevention of ischaemic complications of unstable angina or non- 
Q wave myocardial infarction, 91% of patients received the correct treatment 
dosage of 80mg twice daily and all patients received the correct duration of therapy 
of 2 to 8 days. Eight and a half days of treatment at a dosage o f 80mg twice daily 
was found to be sufficient for the resolution of deep vein thrombosis. Sixty-five 
percent of orthopaedic and 62% of gynaecological patients received pre-operative
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doses, while patients undergoing vascular surgery did not receive any pre-operative 
enoxaparin. Sixty-one percent of all patients received their post-operative dose of 
enoxaparin at least 12 to 24 hours after surgery once haemostasis was established. 
Twenty-five percent of the operative orthopaedic patients received epidural 
anaesthesia. Concurrent non-steroidal anti-inflammatory drug treatment did not 
appear to cause increased bleeding. Concerning patient safety, 13% experienced 
injection site reactions, 8% thrombocytopenia, 4% thrombocytosis and 24% 
haemorrhages (major and minor).
Conclusion:
Usage of enoxaparin dosages and durations comply with the recommended norms. 
Consideration has been given to the timing of enoxaparin in relation to the time of 
surgery in order to minimise bleeding. More caution is advised with regard to 
timing of enoxaparin dosage in relation to epidural anaesthesia and the need for 
epidural anaesthesia concurrent with enoxaparin carefully evaluated. Monitoring of 
platelet counts is advised. It is also recommended that the 80mg prefilled syringe be 
made available especially for treatment dosages and that nursing staff and patients 
be educated on correct administration and precautions so that injection site
reactions can be minimised.
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1 Introduction
1.1 The Concept of Pharm aceutical C are
Traditionally the provision of a pharmaceutical service has encompassed the 
efficient supply o f the correct medication to a patient at the right time. Recently, 
however, the role o f pharmacy has taken on a wider responsibility to include the 
application o f pharmaceutical expertise towards maximising drug efficacy and 
minimising drug toxicity.1
Concern for the outcome o f treatment in a patient, characterises the practice o f 
clinical pharmacy and has led to the concept o f  pharmaceutical care. The term 
“pharmaceutical care” was coined in the United States by Heppler and Strand,2 
who defined it as the responsible provision o f drug therapy for the purpose of 
achieving definite outcomes which improve the patient’s quality o f  life. It 
involves a process by which a therapeutic plan is designed, implemented and 
monitored to produce specific therapeutic outcomes for the patient.1
1.2 Drug Utilisation Review
Clinical pharmacy is also characterised by review o f medication orders to 
ensure safe prescribing. Prescriptions are reviewed by clinical pharmacists for 
accuracy, appropriateness and safety. Prescription or drug utilisation review is a 
retrospective check on prescribed medication with a view to ensuring cost 
effectiveness o f  medicines. The key benefits o f drug utilisation review is to 
audit prescribing, to give feedback on prescribing practice and by so doing,
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obtain peer review as well as to maximise clinical benefit to a patient at least 
cost.1
Addition o f a new drug to a hospital and its subsequent availability is a 
circumstance under which the prescribing patterns and subsequent outcomes can 
be monitored. Low molecular weight heparins are examples o f  such 
medications, which have only just recently been added to hospital formularies. 
At the Johannesburg General Hospital, enoxaparin is the low molecular weight 
heparin, which has been added to the hospital formulary. The Johannesburg 
General Hospital is a teaching hospital in Johannesburg with an 897 approved 
bed capacity, but which has 1163 beds in use. Addition o f  a medication to a 
hospital formulary must be justified by appropriate knowledge o f  its use. 
Inappropriate prescribing and monitoring may jeopardise patient care and lead 
to unnecessary costs. For these reasons, enoxaparin, which has recently been 
added to hospital formularies was considered to be an appropriate drug, o f 
which to conduct a drug utilisation review.
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2 Review of the literature
2.1 Venous thromboembolism
Venous thromboembolism, constituting deep vein thrombosis (DVT) and 
pulmonary embolism (PE), is a major health problem with two possible serious 
outcomes. PE can be fatal and DVT can lead to post thrombotic venous 
insufficiency which has an effect on the health and quality o f  life o f  patients.3
In the general population, epidemiological data indicate that the frequency o f 
DVT is approximately 160 per 100 000 and for fatal autopsy-detected PE, 50 
per 100 000.4’5 Following autopsy o f hospital cases, PE has been revealed as the 
cause o f death in 10% o f cases, DVT being present in 83% o f cases o f  which, 
despite 18% showing clinical evidence o f thromboembolism, only 3% were 
further investigated.6
Mortality rates are worsened by the fact that PE develops without prior warning 
and in the absence o f any established life-threatening conditions in one fourth to 
one half o f  these patients.7 Although anticoagulant therapy for venous 
thromboembolism is highly effective, one cannot rely on treatment o f PE to 
save the maximal number o f lives. Two thirds o f patients who ultimately die o f 
PE also succumb within 30 minutes after the acute event, too soon for any 
anticoagulant treatment to have an effect on mortality.8 Prevention o f PE and 
DVT therefore becomes a priority for the medical profession.
3
2.2 Risk categories for venous thromboembolism.
Patients can be classified into high, medium or low risk o f  developing 
thromboembolism, defined by frequency o f  thrombosis as below.7
Table 1 :The definition o f risk factors (modified from Salzman and Hirsh.)
Category Frequency o f ca lf 
vein thrombosis
Frequency o f  
proximal vein 
thrombosis
Frequency o f fatal 
pulmonary 
embolism
High Risk 40 - 80 % 1 0 -3 0 % >1%
Moderate Risk 1 0 -4 0 % 1 -1 0 % 0.1 - 1 %
Low Risk <10% < 1 % <0.1 %
The International Consensus Statement for the Prevention o f Venous 
Thromboembolism classifies patients into high, medium or low risk according 
to known clinical risk factors as below:
Table 2: Risk factors according to clinical risk factors in non-orthopaedic 
patients
Risk category General
surgery
Gynaecology Obstetrics Medical
patients
HIGH Major general 
surgery, 
age > 60
Major
gynaecological 
surgery, 
age > 60
History o f 
DVT/PE
Stroke 
Age>70 
Congestive 
cardiac failure
Major general 
surgery, 
age 40-60 
and cancer or 
history o f 
DVT/PE
Major
gynaecological 
surgery, 
age 40-60 and 
cancer or 
history of 
DVT/PE
Shock
History o f 
DVT/PE
Thrombophilia Thrombophilia Thrombophilia Thrombophilia
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Table 2(Cont’d): Risk factors according to clinical risk factors in non-
orthopaedic patients
Risk category General
surgery
Gynaecology Obstetrics Medical
patients
M ODERATE Major general 
surgery, age 
40-60 without 
risk factors
Major
gynaecological 
surgery, 
age 40-60
Age > 40 years Immobilised 
patient with 
active disease
Minor surgery 
age > 60
Major
gynaecological 
surgery 
age <40 
on oestrogen 
Rx
Cardiac failure
Minor surgery 
age 40-60 with 
history o f 
DVT/PE 
on oestrogen 
RX
Minor surgery 
age > 60
LO W Major general 
surgery, 
age < 40 
No other risk 
factors
Minor
gynaecological 
surgery, 
age <40 
without any 
other
risk factors
Age <  40 
without any 
risk 
factors
Minor medical 
illness
Minor surgery 
age 40-60 
No other risk 
factors
Minor
gynaecological 
surgery, age 
40-60 without 
any other risk 
factors
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The risk in surgical patients
Patients who undergo operative procedures are at risk o f  developing venous 
thromboembolic disease. This can be attributed to three mechanisms: the 
activation o f clotting factors in injured tissues causing hypercoagulability, 
immobilisation associated with trauma or surgery causing stasis o f  blood in the 
legs and lastly, the injuries or surgery itself may damage the intimal layer o f 
blood vessels.8
The risk o f developing venous thromboembolic disease following surgery is 
further increased by age, obesity, malignancy, previous history o f venous 
thrombosis, varicose veins, lower limb surgery, heart disease, prolonged 
immobilisation and thrombophilic states. The risk is also increased by the 
duration o f the operation, the type o f anaesthesia, pre-operative and post­
operative immobility, level o f hydration and the presence o f sepsis.3
The risk in gynaecology and obstetrics
The risk after gynaecological surgery is o f the same magnitude as for general 
surgery. For benign gynaecological surgery and vaginal procedures, the 
incidence o f thromboembolic complications is much lower. Following 
gynaecological cancer surgery however, PE accounts for about 20% o f 
perioperative hysterectomy deaths.3
Combined oral contraceptive preparations containing 50 micrograms or more o f 
oestrogen were shown to be associated with an increased risk o f  postoperative 
thromboembolism.9,10 Recently, those containing 35 micrograms or less have 
also been shown to increase the risk o f venous thromboembolism by
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2.3 Low m olecular weight heparins (LMW Hs)
Low molecular weight heparins were developed as a result o f two major 
observations in the mid 1970’s and early 1980’s. The first was that low 
molecular weight heparin fractions prepared from unfractionated heparin 
progressively lose their ability to prolong the activated partial thromboplastin 
time (aPTT) while retaining their ability to inhibit activated factor X .16 The 
second was the observation that, for an equivalent antithrombotic effect, low 
molecular weight heparins produce less bleeding in experimental models than 
unfractionated heparin.16
Like unfractionated heparin, low molecular weight heparins are 
glycosaminoglycans consisting o f chains o f  alternating residues o f  D- 
glucosamine and uronic acid, either glucuronic acid or iduronic acid. They are 
produced from unfractionated heparin by controlled enzymatic or chemical 
depolymerization processes to yield chains with a mean molecular weight o f 
about 5000 daltons.18
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2.4 E noxaparin
Chemistry
Enoxaparin is a low molecular weight heparin with a 4-eno-pyranosuronate 
sodium moiety at the non-reducing end o f the chain as shown in figure l . 17
Enoxaparin is prepared from porcine heparin by benzylation followed by  
alkaline depolymerisation. As the above figure indicates for enoxaparin, each 
low molecular weight heparin comprises a number o f  components whose 
molecular weights vary within a certain defined range. The apparent mean 
molecular weight o f  enoxaparin is 3.8 kD as determined by HPLCV-gel 
permeation chromatography with ultraviolet detection.17
COONa
n «• 3-20 
G =  glucosamine 
U =  ironic acid
Figure 1: Chemical structure o f enoxaparin
Mechanism of action
Antithrombotic agents exert their action by activating antithrombin in the 
clotting mechanism. Antithrombin is a circulating protease inhibitor that binds 
to serine proteases in the coagulation system such as active forms o f factors IX, 
X, XI and XII, thereby blocking their activity as clotting factors in the clotting 
cascade and preventing the formation o f a clot.
This interaction o f low molecular weight heparins with antithrombin is mediated 
by a unique pentasaccharide sequence that is randomly distributed along the 
heparin chains.18 In comparison to one third o f the chains o f unfractionated 
heparin containing the pentasaccharide sequence, only 15 to 25% o f the chains 
o f low molecular weight heparins contain the pentasaccharide sequence, which 
enables interaction with antithrombin. Binding o f the pentasaccharide to 
antithrombin causes a conformational change in antithrombin resulting in an 
increase o f  approximately 1000 fold in its affinity for activated factor X. The 
difference between unfractionated heparin and low molecular weight heparin is 
in their relative inhibitory activity against factor Xa and thrombin.18
Heparin and tow molecular weight heparins bind to antithrombin thereby 
inhibiting the action o f factor Xa. Any pentasaccharide containing heparin chain 
can inhibit the action o f factor Xa by binding to antithrombin and causing a 
conformational change. In comparison to inactivate thrombin, heparin must bind 
to both antithrombin and thrombin, thereby forming a ternary complex, as 
shown in figure 2.
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Figure 2. Catalysis o f antithrombin-mediated inactivation o f thrombin or 
Factor Xa by unfractionated heparin or low molecular weight heparins.
(From Weitz JI: Low-molecular-weight heparins. N Engl J Med 1997; 337:688-698.)
11
The ternary complex can only be formed by pentasaccharide containing heparin 
chains composed o f at least 18 saccharide units. Most o f  the chains o f 
unfractionated heparin are at least 18 saccharide units long. On the other hand, 
less than half o f  those o f low molecular weight heparins are o f  sufficient length 
to bind to both antithrombin and thrombin.18
Therefore, unlike unfractionated heparin which has the same activity against 
factor Xa and thrombin, low molecular weight heparins have a greater activity 
against factor Xa.18
Pharm acokinetics
Enoxaparin is highly and predictably absorbed following subcutaneous 
administration, the absorption being linear within a dose range o f 20 to 80mg. 
The absolute bioavailability o f  subcutaneous enoxaparin, in terms o f anti-factor 
Xa, is approximately 91%, three times higher than that o f  low dose 
unfractionated heparin, whose bioavailability is about 29%.17 This enhanced 
bioavailability is due to their reduced binding to plasma proteins, endothelial 
cells and macrophages.
The volume o f  distribution is estimated to be between 5,2 and 9,3/ and total 
body clearance ranges from 0,83 to 1,86 //h.17 Enoxaparin is mainly excreted 
renally and possesses the advantage o f dose independent elimination.17 In 
contrast, heparin is eliminated in a dose-dependent fashion i.e. a rapid saturable 
phase reflecting hepatic uptake and a slower phase corresponding to renal
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clearance. The plasma half-life o f enoxaparin is 4,5 hours, whereas that o f 
heparin is 1 to 2 hours.17 The terminal phase elimination half-life o f  enoxaparin, 
based on anti-factor Xa activity, has ranged between 3 and 6 hours following 
subcutaneous administration to volunteers. Although there are discordant 
findings in the literature, it appears that in the presence o f  chronic severe renal 
failure, enoxaparin clearance may be halved and elimination half-life doubled.17
The reduced binding o f enoxaparin to macrophages explains why enoxaparin is 
not cleared by hepatic mechanisms to the same extent as unfractionated heparin 
and why renal clearance is slower than hepatic uptake, resulting in a longer half- 
life for enoxaparin.17
In contrast heparin binds to endogenous plasma proteins such as histidine-rich 
glycoprotein, polymeric vitronectin, fibronectin, platelet factor 4 (released from 
activated platelets) and to high molecular- weight multimers o f  von Willebrand 
factor, the storage form o f  von Willebrand factor that is released from platelets 
and endothelial cells. This binding o f heparin to plasma proteins makes it less 
available to interact with anti-thrombin, thereby reducing its anticoagulant 
activity. The wide variability in plasma concentrations o f  heparin-binding 
proteins, makes the anticoagulant response o f  heparin unpredictable. Because o f 
the unpredictable anticoagulant response, careful laboratory monitoring is 
necessary when unfractionated heparin is given in therapeutic doses.
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2.5 Advantages of enoxaparin vs heparin
Enoxaparin differs from heparin in the following ways:
a) a single daily dose is sufficient for prophylaxis, since its half-life is twice as 
long as that o f heparin,5
b) intravenous administration o f enoxaparin is not necessary in the treatment o f 
DVT as bioavailability following subcutaneous administration is 100%,5
c) there is less variation in response in different individuals with a  fixed dose 
o f enoxaparin,5
d) there is a lower risk o f  fatal PE (0,02% with enoxaparin) than with heparin
(0,12%),5
e) enoxaparin has less effect on platelets as previously mentioned, as well as 
on vascular permeability.5
2.6 Efficacy of enoxaparin in orthopaedic surgery.
Venous thromboembolism is a complication which follows major orthopaedic 
surgical procedures. Without prophylaxis, the incidence o f DVT is 
approximately 50% for elective hip replacement and approximately 47% for 
total knee replacement.3
In hip replacement surgery the formation o f thrombi is multifocal, occurring 
principally in the surgically manipulated leg, where there is venous stasis and 
trauma to blood vessels. Because 50% of the thrombi occur in the proximal vein 
localized to the femoral vein at the site o f the surgery, the risk o f PE is high. It is
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important therefore to utilise an anticoagulant regimen which is capable o f 
preventing the initiation and propagation o f venous thrombi without increasing 
the risk o f postoperative bleeding or interfering with wound healing.
Fixed, low dose regimens (5000IU subcutaneously every 8 to 12 hours) o f 
unfractionated heparin, have proven effective in reducing the incidence o f post­
operative DVT and potentially fatal PE.19 Collins et al.20 however, found that 
patients undergoing hip replacement surgery showed suboptimal results on 
heparin therapy.
Following the results o f  a double-blind trial in which Kakkar and Murray21 
showed a reduction in the rate o f  thrombosis in general surgical patients from 
7,5% in patients given fixed dose heparin to 2,5% in patients given low 
molecular weight heparin, Turpie et al. conducted a double-blind randomised 
trial in 100 patients evaluating the efficacy o f enoxaparin in a dose o f 30mg 
twice daily vs placebo following elective hip surgery. They found that there was 
a reduction in total thrombi from 51,3% in the placebo to 10,8% in the 
enoxaparin group (p<0,001), and also a reduction in proximal vein thrombi from 
23,1% to 5,4%, indicating that enoxaparin is effective in reducing the risk o f 
clinically important thromboembolic events in patients undergoing elective hip 
replacement.
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Leclerc et al.23carried out a similar randomised study in 111 patients undergoing 
knee surgery. Patients received 30mg twice daily o f enoxaparin or placebo. The 
rate o f DVT was reduced from 65% to 20% ( p<0,01). No difference was 
detected in bleeding between groups.
Randomised trials comparing enoxaparin versus heparin have been carried out 
by Planes et al.24 as well as Levine et al.25 Planes et al. randomised 237 patients 
undergoing elective hip replacement to either 40mg daily o f enoxaparin or 5000 
IU three times daily o f unfractionated heparin, both regimens commencing pre- 
operatively. The rate o f DVT was reduced from 25% with unfractionated 
heparin to 12,5% with enoxaparin (p< 0,01). A similar reduction rate (23% in 
heparin group vs 19% in enoxaparin group) was shown by Levine et al.25 who 
randomized 665 hip replacement patients to either enoxaparin 30mg twice daily 
or 7500 IU twice daily o f unfractionated heparin, both regimens also 
commencing post-operatively. The difference was not statistically significant, 
but the incidence o f clinically important bleeding was shown to be significantly 
higher in the heparin group than in the enoxaparin group (9% vs 5%; p< 0.05).
Spiro et al.26carried out a dose ranging study in 572 elective hip replacement 
patients who received one o f the following dosage regimens o f enoxaparin: 
lOmg once daily; 40mg once daily or 30mg twice daily. They found that the 
incidence o f venous thrombosis was 31% in the group receiving lOmg once 
daily, 14% in the group receiving 40mg once daily and 11% in those receiving 
30mg twice daily. The results o f the above trials are summarised in Table 3.
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Table 3: Summary o f  pivotal studies o f  enoxaparin usage in orthopaedic patients
Author N Type o f  study Dose Dose o f Deep vein
comparator thrombosis
rates
Turpie22 100 Comparative 30mg twice Placebo 51% placebo vs
in elective 
hip surgery
daily 11% enoxaparin
Leclerc23 111 Knee surgery 30mg twice Placebo 65% placebo vs
daily 20% enoxaparin
Planes24 237 Elective hip 40mg daily Heparin 25% heparin vs
replacement 5000 U tds 12,5% enoxaparin
Levine23 665 Hip 30mg twice Heparin 23% heparin vs
replacement daily 7500 U b d 19% enoxaparin
Spiro26 572 Elective hip lOmg daily 25%
replacement 40mg daily 14%
30mg twice 
daily
11%
These pivotal studies have contributed to establishing the dosage and directions 
for the use o f enoxaparin in the prophylaxis o f  venous thrombosis in 
orthopaedic surgery. The recommended dosage is 40mg (0,4ml) once daily by 
subcutaneous injection. The first injection should be given 12 hours pre- 
operatively. Treatment is continued for 7 to 10 days after surgery or as long as 
there is a risk o f venous thromboembolism and until the patient is ambulatory. 
Continued therapy with 40mg once daily for 3 weeks following the initial 
therapy has proven to be beneficial in total hip replacement. The benefit of 
extended prophylaxis o f enoxaparin up to a month after, rather than only during 
hospitilisation is supported by two randomised studies: Bergqvist et al.28 and 
Planes et al.29
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2.7 Enoxaparin in the treatment of deep vein thrombosis.
Besides its use in the prevention o f DVT, enoxaparin has also recently been 
shown to be safe and effective in the treatment o f DVT.
Acute DVT is usually treated by the administration o f intravenous 
unfractionated heparin for 5 to 7 days, followed by oral anticoagulants started 
during hospitalisation and continued for a minimum o f 3 months. The 
anticoagulant response to heparin is variable and the dosage o f heparin needs to 
be carefully titrated to achieve an activated partial thromboplastin time (aPTT) 
to above 1.5 times the control values. Daily monitoring o f (aPTT) times 
prolongs hospital stay o f the patient and increases hospital costs. Also, the need 
for administration o f heparin by the intravenous route does not allow early 
ambulation and is also troublesome for the patient.
A number o f recent randomised studies have shown that weight adjusted fixed 
dose low molecular weight heparins given subcutaneously are as effective as 
intravenous unfractionated heparin in the initial treatment o f  hospitilised 
patients with DVT. The added advantage o f once daily subcutaneous 
administration without laboratory monitoring overcomes many o f the 
disadvantages o f heparin.
The studies have been summarised in a meta-analysis by Lensing et al.31 who 
compared reduction in thrombus size, incidences o f  major bleeding, recurrence
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rates o f  clinically apparent DVT and mortality risk reduction o f low molecular 
weight heparins versus that o f  heparin.
They found that venographically determined thrombus size (5th to 7th day after 
treatment was started) was reduced in 64% o f patients receiving low molecular 
weight heparins compared with 50% in those receiving unfractionated heparin 
(p<0.001). Similarly there was an increase in thrombus size in 6% o f patients 
receiving low molecular weight heparins compared with 12% in those receiving 
unfractionated heparin (p<0.001).
The recurrence rate o f clinically apparent DVT was lower in those patients 
receiving low molecular weight heparins (LMWH) versus unfractionated 
heparin (UH) i.e.(UH 7% vs LMWH 2,7%; risk reduction 61%; p<0,005), as 
was mortality (UH 8,1% vs. LMWH 4,3%; risk reduction 48%; p<0,03).32 The 
incidence o f major bleeding was 3,2% in the patients receiving unfractionated 
heparin compared with 0,9% in those receiving low molecular weight heparins 
(risk reduction 68%; p< 0.005).
The manufacturer’s recommendations concerning die treatment o f  DVT are that 
a dose o f lm g/kg should be given subcutaneously every 12 hours. Oral 
anticoagulant therapy should be initiated when appropriate and enoxaparin 
treatment should be continued until a therapeutic anticoagulant effect has been 
achieved i.e. International Normalisation Ratio (INR) =2 to 3. Enoxaparin 
treatment is usually prescribed for between 5 and 10 days.30
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2.8 Enoxaparin in unstable angina
The recommended dose o f enoxaparin for the prevention o f ischaemic 
complications o f  unstable angina or non-Q-wave myocardial infarction is 
lmg/kg every 12 hours by subcutaneous injection, administered concurrently 
with aspirin (100 to 325mg once daily). Treatment with enoxaparin in these 
patients should be prescribed for a minimum o f 2 days and continued until 
clinical stabilisation. The usual duration o f treatment is 2 to 8 days.30
2.9 Side-effects and special precautions of enoxaparin.
The use o f enoxaparin is however not without adverse effects.
During enoxaparin therapy, bleeding may occur in the presence o f associated 
risk factors such as organic lesions liable to bleed, invasive procedures or the 
use of medications affecting haemostasis. The origin o f  the bleeding should be 
investigated and appropriate treatment instituted.30 An audit examining the 
cause o f post-operative bleeding in patients with low molecular weight heparins 
suggests that up to 80% o f  bleeding episodes are associated with initiation o f 
therapy too soon after surgery. It is therefore advisable that low molecular 
weight heparins should not be given for at least 12 to 24 hours after surgery, in 
order to allow haemostasis to be established.
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Enoxaparin for DVT prophylaxis has been shown to be responsible for 
increased post-operative bleeding as compared to a control group. In a case 
control study 33o f 156 patients receiving enoxaparin 30mg twice daily as post­
operative prophylaxis for arthroplastic procedures, with matched controls 
receiving no anticoagulation, the total complication rate was 23,7% in the 
enoxaparin group compared to 16,5% for the control group. The major 
complication rate was 3,3% (n=5) in the enoxaparin group compared to 1,3% 
(n=2) for controls. Neither reached statistical significance due to sample size 
limitations. There was one case o f  epidural haematoma requiring surgical 
decompression in the enoxaparin group, as well as 4 major haemorrhages, with 
1 also associated with thrombocytopenia. In the control group, 1 major 
haemorrhage and 1 incisional haematoma were reported. The post-operative 
haematocrit drop was significantly greater in patients who received enoxaparin 
(17,9% vs 14,1%; p=0.003) and significantly more transfusions were required ii 
single joint procedures in the enoxaparin group (p=0.02). The complication rate 
was significantly greater i f  the enoxaparin was given fewer than 10 hours after 
surgery.
Recommendations from these authors are that the first dose o f enoxaparin 
should be administered at least ten hours after surgery33 and that enoxaparin 
should not be used with indwelling catheters or epidural anaesthesia.
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The package insert o f  enoxaparin states as a warning that there have been cases 
o f intraspinal haematomas reported with the concurrent use o f enoxaprin and 
spinal/epidural anaesthesia resulting in long-term or permanent paralysis.30 The 
risk o f  these events is increased by use o f indwelling epidural catheters for 
administration o f analgesia or the concomitant use o f agents affecting 
haemostasis such as non-steroidal anti-inflammatory (NSAID) drugs, platelet 
inhibitors or other anticoagulants. The risk is increased by traumatic or repeated 
epidural or spinal puncture.
More than 30 reports have been submitted to die FDA describing neurologic 
injury, including long-term or permanent paralysis with the concurrent use o f 
enoxaparin and spinal or epidural anaesthesia.Those affected were mainly 
elderly women undergoing orthopaedic surgery. The risk in the United States 
may also be higher due to the higher recommended dosages used there i.e. 30mg 
twice daily for prophylaxis o f thromboembolism, which is 20mg more than the 
recommended prophylactic dose o f 40mg daily in South Africa.
It is recommended therefore that clinicians should consider fully the potential 
benefit versus risk before the use o f epidural anaesthesia in patients 
anticoagulated or scheduled for anticoagulation with enoxaparin. If the benefit 
outweighs the risk, then the lowest effective dose should be used, and the use of 
enoxaparin be interrupted at least 10 to 12 hours45 before and after epidural 
block. Should an indwelling catheter be used, the timing o f catheter removal is 
extremely important. Removal should be delayed for at least 10 to 12 hours after
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a dose o f enoxaparin. Subsequent dosing should not occur for at least 2 hours 
following catheter removal.45
The need for alteration in dose o f enoxaparin in patients with renal failure has 
not been fully evaluated. Preliminary evidence from controlled investigation in 
both normal volunteers and patients with chronic renal failure suggests that the 
elimination half-life in renal failure patients may be prolonged as much as 2 
fold, with a slightly elevated maximal anti-factor Xa activity.17 In subjects with 
moderate renal impairment (creatinine clearance 30 to 80 mls/min), anti-factor 
Xa apparent clearance values were similar to those in healthy subjects. Apparent 
clearance values were 30% lower in patients with severe renal impairment 
(creatinine clearance less than 30 ml/min) compared to controls. Caution is 
recommended in these patients30 and monitoring by plasma anti-factor Xa 
should be considered.
Symptomatic thrombocytopenia has been reported during first days o f therapy 
with enoxaparin.
Enoxaparin has also been associated with bleeding episodes in 4% (n =23) of 
patients undergoing abdominal or colorectal surgery. Haemorrhage, anaemia, 
and ecchymosis occurred at an incidence o f 7%, 3% and 3% respectively.30
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3 Aims of the study
3.1 Statement of the problem
Because low molecular weight heparins are still fairly new compared to the 
length o f time over which heparin has been available, a drug utilisation study o f 
enoxaparin, a low molecular weight heparin was undertaken. Usage o f 
enoxaparin would be evaluated by monitoring therapy o f enoxaparin, reviewing 
procedures and analysing and interpreting patterns o f use and measuring these 
against pre-determined criteria and standards.
The aim o f this study is to evaluate the utilisation o f enoxaparin therapy thereby 
stimulating improvements in medication use processes and patient safety and 
identifying areas in which further education for health care professionals may be
needed.
Enoxaparin was chosen for the study, because it is a critical drug being 
prescribed frequently in the prevention and treatment o f  thromboembolism and 
despite its advantages over heparin, is still suspected o f presenting a risk. This 
study will also endeavour to identify those factors which may contribute 
towards safer use o f  the drug.
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3.2 Delineation of problem
The criteria investigated were as follows:
Patterns of usage
•  Categories
•  Demographics
• Prophylactic dosage
• Treatment dosage
• Duration o f treatment
• Potential modifications for special populations
• Pre-operative dose interval and association with complications
• Post-operative dose interval and association with complications
•  T im in g  o f  th e  dose o f enoxaparin in relation to epidural anaesthesia
• Administration technique / problems
Concomitant therapy and contra-indications
• Concurrent therapy with non-steroidal anti-inflammatory drugs (NS AIDs), 
salicylates or other anticoagulants
•  U se  u n d e r  co n d itio n s  o f  impaired haemostasis e.g . peptic ulcer etc. 
Tolerability
• Local rea c tio n  at in jec tio n  site (haematoma > 5cm in  diameter)
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•  Effect on haematological indices
•  decrease in haemoglobin o f more than 2g/dl
•  Incidence o f thrombocytopenia -  defined as a decrease in the platelet 
count o f  at least 30% from baseline or a platelet count o f less than 100, 
000 per mm.3 Thrombocytopenia was considered severe if  the platelet 
count was less than 50,000 per mm.3
• Incidence o f haemorrhage
•  Defined as major i f  bleeding was overt and was associated with the need 
for transfusion o f two or more units o f  packed red cells or whole blood 
or with a decrease in the haemoglobin concentration o f 2.0g per deciliter 
or more from the baseline or if  bleeding was retroperitoneal, intracranial 
or fatal.37
• Defined as minor if  bleeding was overt but did not meet the other criteria 
for major haemorrhage.37
• Death from any cause
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4 Materials and methods
Prior to commencing the study, permission to conduct the study was obtained 
from the Committee for Research on Human Subjects o f the University of 
Witwatersrand(see Appendix F), as well from each o f the Department Heads of 
the wards concerned.
4.1 Study design
The study took the form of a prospective descriptive study. Patients were 
recruited consecutively over a 12 week period from patients presenting to the 
following academic teaching wards o f the Johannesburg General Hospital
a) orthopaedic
b) gynaecology
c) vascular
d) medical
The advantage o f carrying out this study prospectively is that it allowed the 
monitoring o f clinical signs (e.g. injection site reactions, administration 
technique) not often recorded in the patient’s medical records.
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4.2 Inclusion criteria
Patients eligible for inclusion from the orthopaedic, gynaecological and vascular
surgical wards were those who;
a) had undergone or be about to undergo a surgical procedure lasting 45 
minutes or more, and
b) had or were receiving enoxaparin for the prevention or treatment o f DVT.
Patients included from the medical wards were those who were receiving
enoxaparin either prophylactically or therapeutically.
4.3 Exclusion criteria
a) Patients receiving heparin or warfarin
b) Patients hypersensitive to enoxaparin
c) Patients who may be unable to be compliant with enoxaparin usage due to 
administration problems i.e. inability to tolerate burning from the 
subcutaneous injections o f  the study medication
d) Patients experiencing any other adverse effects due to enoxaparin
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4.4 Collection of data
A data collection sheet was designed to obtain the relevant data to be evaluated, 
(see Appendix A). An explanation o f the study and permission to extract data 
from the patient’s medical notes was obtained and verified by signed informed 
consent. A copy o f the consent form is provided in Appendix B.
Data was recorded twice weekly from the patients’ medical records until 
enoxaparin therapy was stopped or until the patient was discharged. Information 
collected from the data collection sheet was then tabulated for analysis.
The data collected was verified a second time against copies o f the source 
documentation (patients’ medical records) captured on microfiche. Cross 
referencing with the microfiches also enabled retrospective outlook on the data 
and also enabled tracking o f  patients who had returned to the hospital with 
further complications following the previous admission.
A review o f  the medical records and data collected was made to evaluate the 
following: patient’s age, sex, type o f procedure, type o f anaesthesia, duration o f 
therapy with enoxaparin, the number o f hours pre-operatively the pre-dose o f 
enoxaparin was administered and the number o f hours post-operatively the first 
dose o f enoxaparin was administered. The number o f  units o f  blood, packed 
cells or Haemacel® transfused were recorded. Changes in postoperative 
haematocrit and platelet values were calculated by identifying the baseline pre-
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operative value and the lowest value recorded during the patient’s hospital stay 
and calculating the percentage decrease between these values. If  the patient had 
only one set o f values recorded during the hospital stay, the patient was 
excluded from this part o f the study. Major and minor bleeding complications as 
defined in the criteria were also recorded.
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5. Results
5.1 Patient Categories
M edical
O rth op aed ic
2 6 %
3 5 %  ' ' i  ^
G yn aeco lo g V a s c u la r
ical 2 2 %
17%
F ig u re  3: P a tien t C a teg o ries
T ab le  2: C la ssif ica tio n  o f  p a tien ts  acco rd in g  to  ty p e  o f  su rgery
Type of surgery /Reason for admission N u m b e r o f  
p a tien ts
T otal per 
ca tego ry
1.O rthopaedic
T ota l h ip  rep lacem en t 13
T o ta l k n ee  rep lacem en t 4
O th e r 3 20
2. V ascular
B elo w  k n ee  am p u ta tio n 2
A b o v e  knee  am p u ta tio n 3
F em o ra l su rgery 3
D V T 3
O th er 6 17
3. Gynaecological
T ota l ab d o m in a l h y s te rec to m y 8
O th er 5 13
4. M edical
P ost m y o card ia l in fa rc tio n  &  U n stab le 11
an g in a
D V T 3
O th er 12 26
Total 76 76
T h e  h ig h es t p a tien ts  en ro lled  w ere  m ed ica l p a tien ts  (3 5 % ), fo llo w ed  in 
d ec reas in g  o rd er b y  o rth o p aed ic  (26% ), v a scu la r (2 2 % ) an d  gyn aeco lo g ica l 
(17% ) pa tien ts .
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5.2 Patient demographics
Patient demographics
Orthopaedic Vascular Gynaecological Medical
Category
F ig u re  4 : P a tien t D em ograph ics.
T ab le  5: D e lin ea tio n  o f  p a tien ts  acco rd in g  to  g en d er
Patients Female Male
O rth o p aed ic 13 7
M ean  A ge(y ears) 57,7 ± 18,4 67 ± 11,9
G y n aeco lo g ica l 13
M ean  A ge 54+ 10 ,9
V ascu la r 7 10
M ean  A ge 50 ± 12 62 ± 7,7
M edical 10 16
M ean  A ge 56 ± 17 55±  16
F em ale  p a tien ts  p resen tin g  fo r o rth o p aed ic  p ro ced u res  w ere  ab o u t ten  years 
y o u n g e r th an  th e  co rre sp o n d in g  m ale  pa tien ts . T h is m ak es  sen se  w h en  one  
co n sid e rs  th a t fem ales  are  m o re  p ro n e  to  o s teo p o ro s is  an d  re la ted  bo n e  d iso rders 
th an  m ales. F em ale  p a tien ts  w ith  v ascu la r p ro b lem s w ere  a lso  y o u n g er than  
m ale  p a tien ts  by ap p ro x im ate ly  8 years. O n the  o th e r h an d  m ale  m edical
iBFemale 
□  Male
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p a tien ts  w ere  ab o u t one  an d  a h a lf  years y o u n g er th an  fem ale  m ed ica l patien ts. 
T h is  ties  up w ith  th e  fact th a t m ales are at risk  fo r ca rd io v ascu la r d iso rd ers  at a
n n
y o u n g er age  th an  f e m a le s / ’
5.3 Dose of therapy
T ab le  6: S u m m ary  o f  d o sag es used.
Procedure Dose Number o f  patients receiving(%)
C riteria Results C orrect dose Incorrect
dose
T ota l h ip  
rep lacem en t
4 0 m g  da ily 4 0 m g  da ily 12 (92 ,3 ) 1 (7,7)
T o ta l knee  
rep lacem en t
4 0 m g  d a ily 40m g da ily 4
K nee
am p u ta tio n
4 0 m g  d a ily 4 0 m g  d a ily  
60m g d a ily  
(n=T )
3 (7 5 ) 1 (2 5 )
V ascu la r
su rg ery
4 0 m g  d a ily 4 0 m g  d a ily 6 0
C lau d ica tio n 80m g tw ice  
da ily
60m g tw ice  
daily
2 (1 0 0 )
T rea tm en t o f  
D V T
80m g tw ice  
da ily
80m g tw ice  
daily
7 0
M y o card ia l 
In fa rc tio n  &  
U n stab le  
A n g in a
80m g tw ice  
da ily
80m g tw ice  
da ily
10 1 (9 )
G y n aeco lo g ica l
S u rg ery
4 0 m g  d a ily 4 0 m g  d a ily 13 0
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Orthopaedic patients
Criteria: 40mg daily 27 
Results:
Total hip replacement
O f the 13 hip replacement patients, 92%(12) patients received the correct 
prophylactic dosage o f enoxaparin. One patient should have had the dosage 
modified as the renal function in this patient was deteriorating, but this was not 
done. (See potential modifications for special populations)
Total knee replacement
All knee replacement patients received the correct prophylactic dose o f 40mg 
daily.
Vascular patients
Criteria: Prophylaxis: 40mg daily; Treatment: lmg/kg twice daily27,42 
Results:
Knee amputations
O f the four knee amputation patients, 75% (3) patients received the correct 
prophylactic dose o f 40mg. One patient was given an excessive dosage o f 60mg 
daily.
Vascular surgerv/claudication
Patients undergoing vascular surgery all received correct prophylactic dosages 
o f 40mg daily. A dosage o f 60mg twice daily was prescribed in 2 patients with 
claudication. This treatment dosage is less than the recommended lmg/kg. The 
reason for this reduced dosage is not clear. One vascular patient who was 
anticoagulated with heparin following femoral crossover surgery, received a
34
p ro p h y lac tic  d o se  o f  en o x ap arin  o f  4 0 m g  d a ily  fo r 3 d ay s d u rin g  a w eek -en d  
passou t. D ue  to the  p o ss ib ility  o f  se lf-ad m in is tra tio n  o f  en o x ap arin  b y  the 
p a tien t, th is  p a tien t w as ab le  to  go ho m e fo r the  w eek-end .
Medical patients
9 7
C rite r ia : lm g /k g  tw ice  da ily  
R e su lts :
T rea tm en t o f  D V T
A ll p a tien ts  rece iv in g  en o x ap arin  fo r trea tm en t o f  D V T  rece iv ed  the correct 
trea tm en t d o se  o f  8 0 m g  tw ice  daily .
M y o card ia l In fa rc tio n
O f  the  e lev en  m y o card ia l in farc tion  p a tien ts  in v estig a ted , 91%  o f  patien ts  
rece iv ed  the  co rrec t dose  o f  80m g tw ice  daily . O ne p a tien t h ow ever, received  a 
dose  o f  4 0 m g  tw ice  daily . A lthough  th is m ay  have been  due  to the fact that this 
p a tien t had  lost one lim b, it w o u ld  no t ju s tify  h a lv in g  the  reco m m en d ed  dose.
Gynaecological surgery.
C riteria : 4 0 m g  once  da ily  3,27
R e su lts :T he g en e ra l tren d  in th is w ard  w as to ad m in is te r a p re-o p e ra tiv e  dose 
fo llo w ed  b y  o n e  ad d itio n a l dose  afte r the o p era tiv e  p ro ced u re  and then  early  
m o b ilisa tio n  o f  the  p a tien t to red u ce  the risk  o f  th ro m b o sis  ra th e r than  
co n tin u a tio n  o f  th ro m b o p ro p h y lax is .
Sum m ary:
A  to ta l o f  five  p a tien ts  (6 .6% ) w ere  no t dosed  acco rd in g  to th e  c rite ria .T h ese  
co m p rised  5%  o f  o rth o p aed ic , 9%  o f  m ed ical and  5 .9%  o f  v a scu la r patien ts.
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5.4 Duration of treatm ent
T able  7: D u ra tio n  o f  trea tm en t
Procedure Duration o f therapy(days) Number o fpatients receiving(n)
C r i t e r ia R e s u l t
( A v e r a g e
d u r a t io n )
C o r r e c t
d u r a t io n
I n c o r r e c t
d u r a t io n
U n k n o w n
Total hip 
replacem ent
7 tolO 9.25 10 2 1
Total knee 
replacem ent
7 to 10 11.5 4
Knee
amputation
7 to 10 17.7 0 5
Vascular
surgery
7 5 6
Claudication 7 3.5 2
Treatm ent o f 
DVT(without 
additional risks)
5 to 10 5.75 2 2
(1 medical 
patient & 
1 vascular
1
(additional 
risk factor)
M y o card ia l 
In fa rc tio n  & 
U n stab le  
ang ina
2 to  8 6.27 11 0 0
M ix ed  m itra l 
valve  p a tien ts
2
(additional
risk
factors)
O rthopaedic surgery
C rite r ia : R eco m m en d ed  d u ration  o f  trea tm en t in o rth o p aed ic  su rg e ry  is from  7 
to 10 days afte r su rg e ry  o r as long  as there  is a risk  o f  th ro m b o em b o lism  and 
until the  p a tien t is am b u la to ry .27
R e su lts : O f  the  jo in t  rep lacem en t pa tien ts  in v estig a ted  (n =  17), 13 pa tien ts 
un d erw en t h ip  rep lacem en t su rgery  and the average  d u ratio n  o f  trea tm en t w as 
9,25 days w h ich  falls w ith in  the recom m ended  du ration . T w o p a tien ts  (12% ) 
rece iv ed  trea tm en t for an in su ffic ien t length  o f  tim e i.e. less than  7 days i.e.(4  
and 6 days). K nee  rep lacem en t pa tien ts  received  trea tm en t for an average  o f  
11,5 days.
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T reatm en t w as  o m itted  in  2 pa tien ts  (3 days and  1 d ay  resp ec tiv e ly ) due to n o n ­
av a ilab ility  o f  d rug .
Vascular patients
C rite r ia : T h e  av e rag e  d u ra tio n  fo r p ro p h y lax is  w ith  en o x ap arin  at a d o sage  o f  
4 0 m g  d a ily  fo r fem oral su rg ery  is 7 day s.42 T h e  av erag e  d u ra tio n  for trea tm en t 
o f  D V T  is 5 to  10 d ay s .27
R e su lts : P a tien ts  w h o  un d erw en t v ascu la r su rg e ry  rece iv ed  en o x a p an n  for an 
av erag e  o f  5 d ays, 2 days less th an  the reco m m en d ed  d u ratio n  o f  7 days. T his 
co m p rised  100%  (m=6) o f  the  v ascu la r su rg e ry  pa tien ts . P a tien ts  w ith  p roven  
D V T  w ere  trea ted  w ith  80m g o f  en oxaparin . In one p a tien t th e rap y  for 2 days 
w as su ffic ien t to  re so lv e  the  th rom bosis . H o w ever, in p a tien ts  w ith  additional 
risk  fac to rs i.e  re tro v ira l s ta tus, trea tm en t for up to 7 days w as necessary .
F ive p a tien ts  had  k n ee  am p u ta tio n  su rgery  and w ere  also  can d id a tes  for 
p ro p h y lax is  w ith  en oxaparin . D ue to their increased  risk  fac to r o f  p ro longed  
im m o b ilisa tio n , d u ra tio n  o f  th erap y  in these  p a tien ts  w as lo nger than  10 days 
and w as g iv en  fo r an average  o f  17 days.
P a tien ts  trea ted  fo r aneu rysm , w ere g iven  the co rrec t trea tm en t dose  o f  80m g 
tw ice  d a ily  fo r 12 days.
P a tien ts  w ith  c lau d ica tio n  w ere  treated  for an in su ffic ien t leng th  o f  tim e (3 and 
4 days).
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In v a scu la r p a tien ts , h ep a rin  co n tinues to  b e  the  th ro m b o p ro p h y lac tic  d ru g  o f  
first cho ice . C lin ic ian s  here  p refe rred  to m o n ito r th e  co ag u la tio n  p ro file  o f  the 
p a tien t and  ad ju st the  dose  o f  h ep arin  acco rd in g ly , th e reb y  k n o w in g  the status o f  
the  p a tien t. T h is  w as g en era lly  the case  w h ere  there  w as a h ig h er risk  for 
ex am p le , w h en  su rg e ry  invo lved  the fem oral o r iliac a rte ries o r w hen  there  w as 
a risk  o f  g an g ren e  o r a th rea ten ed  lim b. E n o x ap arin  is h o w ever, used  in patien ts  
u n d erg o in g  c a lf  v e in / p ro x im al surgery.
E n o x ap arin  is also  used  in som e vascu la r p a tien ts  to  enab le  a tran sien t period  o f  
an tico ag u la tio n  i.e. ov er the w eek-end . H o w ever, it is no t gen era lly  
reco m m en d ed  to  use  h ep arin  and low  m o lecu la r w e ig h t hep arin s  
in te rch an g eab ly .
Gynaecological patients
C rite r ia : 4 0 m g  d a ily  3’27
R e su lts : D u ra tio n  o f  trea tm en t in gynaeco lo g ica l p a tien ts  w as lim ited  to 2 days 
i.e. o n e  d o se  p re -o p e ra tiv e ly  and one  d o se  p o s t-o p era tiv e ly . T h is  w as due to 
early  m o b ilisa tio n  o f  p a tien ts  as w ell as due to  red u ced  h o sp ita l stay . The 
av erag e  leng th  o f  h o sp itilisa tio n  for a h y s te rec to m y  is 3 to  5 days.
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Medical patients
Unstable angina or non-O-wave myocardial infarction 
Criteria: The recommended dose of enoxaparin in the prevention of ischaemic 
complications o f unstable angina or non-Q-wave myocardial infarction is 
lmg/kg every 12 hours administered concurrently with aspirin. Treatment in 
these patients should be prescribed for a minimum of 2 days and continued until 
clinical stabilisation (usual duration being 2 to 8 days).27 
Results: O f the myocardial infarction patients investigated (n=l 1), all patients 
received the correct dose of 80mg twice daily for an average o f 6,27 days. This 
falls within the stipulated time interval o f 2 to 8 days. The minimum number of 
days o f therapy was 2 and the maximum number o f days o f therapy were 20. In 
3/11 (27%) of patients, the initial treatment dose was followed by a maintenance 
dose o f 40mg daily for an average o f 6 days. Concurrent treatment with 150mg 
daily o f aspirin was also carried out as per recommendations.
Summary;
In total 13 patients (17%) did not receive the correct duration o f treatment 
according to criteria. These comprised 10% o f the orthopaedic, 58% o f the 
vascular and 12% o f the medical categories.
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5.5 Potential modifications for special populations
Dosing in obesity
C rite r ia : T he n o rm al p ro p h y lac tic  dose o f  4 0 m g  d a ily  is b ased  on  an average 
w eig h t ad u lt o f  70 to  80kg i.e. 0 ,5m g/kg  daily . D o sag e  in p a tien ts  w e ig h in g  
m ore th an  80kg  sh o u ld  be  ad justed  accord ing ly . A 125kg p a tien t should  
there fo re  rece iv e  60m g da ily  as a p ro p h y lac tic  d o se .27,30 
R e su lts : T he p ro p h y lac tic  dose  used in  m ed ical pa tien t M l 2 w as inappropria te . 
T h is  p a tien t w e ig h ed  125kg and w as g iven  o n ly  4 0 m g  o f  eno x ap arin . T his 
p a tien t w as g ro ss ly  obese  and  co n sideration  shou ld  have  b een  g iven  to the ex tra  
w eigh t and  d o sag e  titra ted  acco rd ing  to 0 ,5 m g /k g  daily.
Dosing in renal failure
C rite r ia : D o sag es n eed  to be  reduced  in pa tien ts  w ith  renal d y sfu n c tio n .30 
R e su lts : A d ju s tm en ts  o f  en o x ap arin  dose  shou ld  be  co n sid e red  for pa tien ts  w ith 
severe  im p a irm en t such  as o rth opaed ic  pa tien t, 0 0 4 .
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5.6 Pre-operative dose interval
A cco rd in g  to the m an u fac tu rer, the reco m m en d ed  tim e  o f  the  p re-o p e ra tiv e  dose 
is 12 ho u rs  p rio r to  the  tim e o f  the op era tiv e  p ro ced u re . 27
T h irty -fiv e  p e rcen t o f  e lec tive  o rthopaed ic  su rg ery  p a tien ts  failed  to receive  
their p re -o p e ra tiv e  dose. T he reaso n  for th is w as unkn o w n . S ix ty -tw o  percen t o f  
g y n aeco lo g ica l p a tien ts  rece iv ed  th e ir p re-o p e ra tiv e  doses. N o n e  o f  the  vascu lar 
op era tiv e  p a tien ts  rece iv ed  any  p re-o p era tiv e  dosing . T he reaso n  g iven  for this 
w as to m in im ise  the inc id en ces o f  b leed ing . It is n o t c lear at th is stage i f  th is is 
b ecau se  v a scu la r su rg e ry  carries a g rea ter risk  o f  b leed in g  th an  o ther types o f  
surgery .
T h e  av erag e  p re -o p e ra tiv e  d o se  in terval w as 13.4 hours in th o se  65%  o f  
o rth o p aed ic  p a tien ts  and  62%  o f  gyn aeco lo g ica l p a tien ts  w ho  rece iv ed  a p re ­
o p era tiv e  d o se  o f  eno x ap arin . T h is  is in co m p lian ce  w ith  reco m m en d a tio n s ,27 
w h ich  are th at the  first in jec tio n  shou ld  be g iven  at least 12 h o u rs  pre- 
o p era tiv e ly . T h is  is due  to the  fact that the  p eak  ac tiv ity  o f  en o x ap arin  occu rs 3 
ho u rs  a fte r  ad m in is tra tio n .
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5.7 Distribution of patients according to 12 hourly post-op dose intervals
Table 6: Distribution o f  patients according to 12 hourly post-op dose intervals
No o f  hours 
between post-op 
dose & procedure
n % Rate o f Complication (%)
8 to 13 3 17 100%
14 to 25 11 61 64%
26 to 37 0
38 to 48 3 17 33%
> 4 8 1 5 **
** Since this sample size was small (i.e n =1) , rate of complication was not considered 
representative
C rite r ia : P o s t-o p e ra tiv e  en o x ap arin  dose  shou ld  be g iven  at least 12 to 24 hours 
afte r su rg e ry 18,27,30
R e su lts : S ix ty -o n e  p e rc e n t o f  pa tien ts  rece ived  th e ir  p o s t-o p e ra tiv e  enoxaparin  
dose  co rrec tly , i.e. a t least 12 to 24  hours afte r su rg e ry  i.e. on  th e  d ay  fo llow ing  
the d ay  o f  the  o p e ra tiv e  p ro ced u re , w h en  h aem o stas is  w as estab lished . 
S ev en teen  p e rcen t h o w ev er, rece iv ed  th e ir  p o s t-o p e ra tiv e  en o x ap arin  dose  on 
the sam e d ay  as the  o p e ra tiv e  p ro ced u re  and an o th e r 17% , ap p ro x im ate ly  2 days 
a fte r the  su rgery . A lth o u g h  the  n u m b er o f  p a tien ts  rece iv in g  th e ir  po st-o p era tiv e  
en o x ap arin  do se  in co rrec tly  is sm all, th ere  does ap p ear to be  an  in crease  in 
co m p lica tio n s  i f  the  p o s t-o p e ra tiv e  en o xaparin  dose  is g iven  too  soon  afte r 
surgery .
42
5.8 C oncurrent adm inistration and tim ing of dose of enoxaparin in 
relation to epidural
C rite r ia : T h e  m a n u fa c tu re r’s p ack ag e  in se rt27 o n  en o x ap arin  co n ta in s  the 
fo llo w in g  s ta tem en t as a  w arn ing : as w ith  o th er an tico ag u lan ts , there  h av e  b een  
rare  cases o f  in tra sp in a l haem ato m as rep o rted  w ith  th e  co n cu rren t u se  o f  
en o x ap arin  an d  sp in a l/ep id u ra l an aesth esia  resu ltin g  in  lo n g -te rm  o r p e rm an en t 
p a ra ly sis . T h e  risk  o f  th ese  rare  even ts  m ay  b e  h ig h e r  w ith  th e  use  o f  p o s t­
o p era tiv e  in d w ellin g  ca th e te rs .27 
R esu lts:
T ab le  9: T im in g  o f  do se  o f  en o x ap arin  in  re la tio n  to  ep idu ra l anaesthesia .
Patient Time difference between end of 
epidural block and 1st dose of 
enoxaparin (hours)
Complication
O rtho  4 7 R ed u c tio n  in H b o f  > 
3 ,4g /d l
O rtho  10 23,5 N o  co m p lica tio n
O rtho  11 9 3 U  o f  b lo o d  transfused
O rtho  12 23,5
O rtho  13 23 2 U  b lo o d  &  500m l 
H aem ace l g iven
In  th is  s tudy , 5 p a tien ts  rece iv ed  ep idu ra l an aes th es ia  w h ile  an tico ag u la ted  w ith  
en oxaparin . T w o  o f  th ese  p a tien ts  rece iv ed  th e ir p o s t-o p e ra tiv e  en o x ap arin  
doses w ith in  10 h o u rs  o f  th e  end  o f  the  ep id u ra l b lo ck  and  b o th  o f  th ese  pa tien ts  
h ad  co m p lica tio n s.
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5.9 Administration technique /problems
Criteria: For each injection the needle should be gently introduced to its entire 
length, perpendicular to the skin fold between the thumb and forefinger. The 
whole content of the syringe should be injected gently and progressively into the 
skin fold. The skin fold should be held exactly throughout the whole period of 
each injection. The site o f the injection should be alternated every day. 
Enoxaparin injections should be given into the left and right anterolateral and 
posterolateral abdominal wall and injection sites should be rotated to avoid 
bruising. To minimise bruising, injection sites should not be massaged after 
injection.27
Results: Collection o f data prospectively, enabled the investigator to observe the 
administration of enoxaparin by the nursing personnel. Most senior nursing 
personnel(n = 8/10) administered the injection correctly. Some junior staff (n = 
2/10) however, were seen to be giving enoxaparin incorrectly with the needle at 
an angle. In two patients (2,7%) enoxaparin was administered into the arm. It is 
questionable whether the enoxaparin was given into the subcutaneous tissue or 
into the muscular tissue in these patients.
At least 9 patients (12%) had injection site reactions o f which rubbing o f the 
injections site was identified as the cause in at least 3 o f the patients. Burning on 
injection was reported by at least 2 patients. (2,67%), and was identified to be 
the reason for non-compliance in at least one patient.
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T w o (2 ,7% ) m ed ica l pa tien ts  w ere able  to se lf-ad m in is te r  the ir en o xaparin  
in jec tions, one b e in g  a d iabe tic  accustom ed  to ad m in is te rin g  in su lin  and the 
o ther, a p u lm o n a ry  p a tien t w ho  w as on long te rm  p ro p h y lax is.
5.10 Concom itant therapy and contra-indications.
A t least 4 (5 ,3% ) p a tien ts  w ere  id en tified  to be  on n o n -ste ro id a l an ti­
in flam m ato ry  d ru g s (N S A ID ) m ed ica tio n  in c lu d in g  p iro x icam  and  naproxen . 
T w o o f  these  p a tien ts  w ere  rh eu m ato id  a rth ritis  p a tien ts  and w ere  in add ition  
rece iv in g  m e th o trex a te  and p red n iso lone . D esp ite  th is  there  d id no t appear to be 
a h igh  rate  o f  c o m p lica tio n s  i.e. increased  b leed in g  o r increased  b lood  loss 
asso c ia ted  w ith  co n cu rren t N S A ID  therapy . T hree  p a tien ts  (4%  ) w ere  receiv ing  
co n cu rren t w a rfa rin  fo r an tico ag u la tio n . U su a lly  these  p a tien ts  w ere  being  
w ean ed  from  w arfa r in  on to  en o x aparin  o r v ice versa , w ith  con cu rren t 
m o n ito rin g  o f  th e  IN R  to  o p tim u m  levels befo re  w ith d raw al o f  the w arfarin . 
T h is illu stra te s  th e  use  o f  en o x ap arin  as an tico ag u lan t “b rid g e  th e rap y ” in those 
p a tien ts  w h o  rece iv e  ch ro n ic  oral an tico ag u la tio n  w hen  th ey  n eed  to stop 
w arfa rin  to  u n d erg o  m a jo r su rg ery  o r invasive  p ro ced u res.
N in e  o th er p a tien ts  (1 2 % ) co n cu rren tly  rece iv ed  150m g o f  asp irin  w h ile  on 
eno x ap arin . T h ese  p a tien ts  w ere  c lo se ly  m o n ito red  fo r b leed in g  , in clud ing  
g as tro -in tes tin a l b leed in g . In jec tio n  site b leed in g  o ccu rred  in one  pa tien t w ho 
w as rece iv in g  80m g tw ice  da ily  o f  en o x aparin  and 150m g o f  asp irin . F o llow ing  
th is m in o r h aem o rrh ag e , the trea tm en t dosage o f  80m g tw ice  d a ily  w as changed  
to a p ro p h y lac tic  d o sag e  o f  40m g daily.
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5.11 Local reaction at injection site (haem atom a > 5cm in diam eter)
T en (13% ) p a tien ts  ex p erien ced  in jection  site  reac tio n s  in v o lv in g  h aem atom as 
(co llec tion  o f  b lo o d  u n d er the skin) m ore  th an  5cm  in d iam eter. T w o o f  these 
reac tio n s co u ld  be  c lassified  as ecchym osis  (large, non  e leva ted  b lue  o r purp lish  
p a tch es in  the sk in ) and occu rred  in pa tien ts  w ho  w ere  e ith e r on co n curren t 
an tico ag u la tio n  (h ep a rin  and w arfarin ) o r had  ju s t  been  tak en  o f f  w arfarin . F ive 
o f  the  ab ove  10 p a tien ts  w ere  on  a 80m g tw ice  d a ily  reg im en , and w ere 
rece iv in g  4  in jec tio n s  p e r  day , s ince  the h osp ita l on ly  stocks the 4 0 m g  prefilled  
sy ringes. F o r th ese  p a tien ts , ad m in is tra tio n  o f  the 80m g p refilled  sy ringe tw ice 
d a ily  m ay  b e  co n sid e red  a b e tte r  o p tion  in o rd er to m in im ise  the n u m b er o f  
n eed le  p rick s  p e r  d ay  and  th ereb y  m in im ise  in jec tio n  site  reac tions.
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5.12 Decrease in haemoglobin of more than 2g/dl
T ab le  10: P a tien ts  ex h ib itin g  a d ecrease  in h a em o g lo b in  o f  m ore  than  
2g /d l
Patient Category Drop in 
Hb(g/dl)
Average (g/dl)
0 0 1 O rthopaed ic 4.6
0 0 3 4.2
0 0 4 3.4
0 0 5 2.1
0 0 6 2.1
0 0 7 3.5
0 1 0 4.3
0 1 5 4.8
0 1 8 5.6
0 2 0 4.1 4 .07  ±  1.12
V 15 V ascu la r 2.7
V 16 3.3
V 17 2.9 2 .97  ± 0 .3 1
M i l M ed ica l 2.9
M 15 6.0
M 18 4.7 4 .53 ±  1.56
R e su lts :
T he larg est d ec rease  in h aem o g lo b in  w as in m ed ical p a tien ts  fo llow ed  by  
o rth o p aed ic  p a tien ts  and  then  vascu la r pa tien ts , a lth o u g h  m o re  o rthopaed ic  
p a tien ts  ex h ib ited  a d ecrease  (50% ) than  m ed ical p a tien ts  (12% ).
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5.13 Incidence of thrombocytopenia
C rite r ia : T h ro m b o cy to p en ia : d e fined  as a d ec rease  in th e  p la te le t co u n t o f  at 
least 30%  from  b ase lin e  o r a  p la te le t co u n t o f  less th an  100 000  p e r m m 3and 
co n sid e red  sev ere  i f  the  p la te le t co u n t w as less th an  50 ,0 0 0  p e r  m m 3.
T ab le  11: P a tien ts  ex h ib itin g  th ro m b o cy to p en ia
Patient Diagnosis %plt
drop
Day o f  Rx Causality
M 06 A trial f ib rilla tio n  and m yocard ia l 
in fa rc tio n
76% D 20 P ossib le
M 08 H eartb lo ck /C A B G 65% D 1 4 P ossib le
M i l M itra l v a lve  rep lacem en t 70% D 8 Possib le
M 15 M y o card itis 54% D 4 N ot
related*
M 17 M y o card ia l in fa rc tio n 32% D 4 N ot
related*
V 17 B ila te ra l b e lo w  k n ee  am pu ta tion 62% D 7 N ot
re la ted ”
* This drop was transient and occurred on one day only. Values returned to normal within 48 hours. 
** Patient V I7 had concurrent puerperal sepsis as well as disemminated intravascular coagulation
T h ro m b o cy to p en ia  re la ted  to en o x ap arin  and as d efin ed  in the criteria , w as 
ex p erien ced  b y  4%  o f  pa tien ts . T hese  pa tien ts ex p erien ced  a d ecrease  in p late le t 
coun t o f  m o re  th an  30%  p o ss ib ly  rela ted  to en o x ap arin  th e rap y  w ith  one patien t 
h av ing  severe  th ro m b o cy to p en ia  o f  less than  50 0 0 0 /m m 3. Severe  
th ro m b o cy to p en ia  w as also  exp erien ced  in pa tien t V I 7, bu t th is  w as no t rela ted  
to en o x ap arin  and  p o ss ib ly  re la ted  to the p ic tu re  o f  co ag u lo p a th y  exh ib ited  by 
th is patien t. It is u n fo rtu n a te  that p la te le t coun ts w ere  no t reco rd ed  for the 
o rth o p aed ic  and g y n aeco lo g ica l patien ts.
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5.14 Thrombocytosis
T ab le  12: P a tien ts  ex h ib iting  th ro m b o cy to s is
Patient Diagnosis/
Procedure
Platelet Count/  
% increase
Causality
M 10 L u n g  red u c tio n 70 2 / 208% P o ssib le
M 14 M M V D 30 0 / 2 26% P o ssib le
V 05 A K A 93 0 / 756% N o t rela ted
V 16 B K A 4 4 4 / 260% P o ssib le
P a tien t (V 05) h ad  b een  on  cn o x ap arin  trea tm en t fo r 29  days, b u t a lso  had  
co n cu rren t sep ticem ia , w h ich  m ay  exp la in  the  7 fo ld  in crease  in the  p la te le t 
count.
T h e  rem a in in g  3 (4 % ) p a tien ts  d isp lay ed  in creases  in  p la te le t coun ts. T his is as 
exp ected  since  a sy m p to m atic  and rev e rsib le  in creases in p la te le t coun ts have 
been  d o cu m en ted .
5.15 H aem orrhage
T ab le  13: P a tien ts  ex h ib itin g  haem o rrh ag e
Patient Haemorrhage Resolution
M 04 M ajo r into th igh D ra in ag e  by  re-su rg ery
M21 M ajo r - In tracran ia l N one- pa tien t d ied
M 06 A n g io g ram  site R eso lved
M 07 O ccu lt b lood T rea tm en t s topped
0 1 9 Site  o f  S te im an  P in R eso lv ed
C rite r ia : H aem o rrh ag e  w as defined  as m ajo r i f  b leed in g  w as ov ert and w as 
asso c ia ted  w ith  the  n eed  for tran sfu sio n  o f  tw o o r m ore  u n its  o f  p ack ed  red  cells 
or w h o le  b lo o d  o r w ith  a d ecrease  in the h aem o g lo b in  co n cen tra tio n  o f  2 .0g/dl
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or more from the baseline or if  bleeding was retroperitoneal, intracranial or 
fatal. It was defined as minor if  bleeding was overt but did not meet the other 
criteria for major haemorrhage.37
Major
During the treatment period, major haemorrhage occurred in 2 patients. The first 
was a male patient aged 74 in the orthopaedic group, who experienced 
haemorrhage into the thigh. This patient had hip replacement surgery under 
epidural anaesthesia and received his post operative enoxaparin within 9 hours 
following surgery. He had a decrease in haemoglobin o f 3.4 g/dl and required 
re-surgery to drain 670ml o f blood tinged fluid. This same patient then 
experienced deteriorating renal function, subsequent sepsis and died two months 
later.
The second patient to experience a major haemorrhage was a female patient 
aged 75 in the medical group, who was admitted for treatment o f DVT, was 
further diagnosed with cancer o f the lung and who subsequently developed a 
large cerebral haemorrhage, confirmed on CT scan and who died one month 
after admission to the ward.
Minor
The remaining three haemorrhages are those as identified in the patients’ 
medical record and represent 4% of the total study population.
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T h irteen  p a tien ts  req u ired  b lood  tran sfu sio n s o f  2 or m o re  u n its  o f  p ack ed  cell 
or w h o le  b lo o d  as w ell as experienced  a d rop  in h aem o g lo b in  o f  m o re  than  
2g/dl. A lth o u g h  th ese  d id no t d isp lay  signs o f  o v ert b leed in g , acco rd in g  to the 
c riteria  d iscu ssed  above , these  can be c lassified  as “h ae m o rrh a g e s” as has been  
done b y  o th e r  in v e s tig a to rs . '3 T he to tal in c idence  o f  h aem o rrh ag e  is th en  18/76 
o r 24% . T h is  is in acco rd an ce  w ith  resu lts  seen by  o th er in vestiga to rs.
S am am a et a l37 found  a to ta l in cid en ce  in h aem o rrh ag e  o f  12.6 % in acu te ly  ill 
m ed ica l p a tien ts  w h ile  S haieb  et a l33 found a to ta l co m p lica tio n  rate  o f  23.7 % in 
o rth o p aed ic  pa tien ts .
L ev ine  at a l25 found  an  in c idence  o f  m ajo r b leed in g  at 3 .3 %  fo llo w in g  elective  
h ip  su rgery , w h ile  L eclerc  et a l 23 found an in c idence  o f  m a jo r b leed in g  after 
knee a rth ro p la s ty  at 2 .4%  and  o f  m inor b leed in g  at 28% . It appears therefo re  
that the  in c id en ce  o f  m in o r b leed in g  and co m p lica tio n s does increase  for 
o rth o p aed ic  pa tien ts .
Blood transfusions and haemoglobin decrease of more than 2g/dl
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5.16 Death from  any cause
T ab le  14: D ea th  from  any  cause
Patient Diagnosis
M 08 H eartb lo ck /C A B G D eath  on subseq u en t v isit
M i l M itra l valve  rep lacem en t D eath  on  subseq u en t v isit
M 17 M yocard ia l in farc tion N o t re la ted
M 25 D V T D eath  due to cerebral 
h aem o rrh ag e
0 0 4 H ip rep lacem en t D eath  due to sepsis
V 05 A bove knee am pu ta tion D ea th  due  to sep ticem ia
V 15 A bove knee am p u ta tion D eath
T w o o f  the 4 m ed ica l card iac  p a tien ts  d ied  on su b seq u en t v isits  to the hospital. 
T he rem a in d e r o f  the  above  pa tien ts  d ied  w h ile  th ey  w ere  in  hosp ita l and 
ad m itted  fo r the  o rig in a l d iagnosis . T here  w ere  tw o  dea ths in five o f  the patien ts 
u n d e rg o in g  k n ee  am p u ta tio n s, b ila te ra l am p u ta tio n s ca rry in g  a g rea te r  risk  than 
sing le  leg  am p u ta tio n s. T h e  one  death  that w as p ro b ab ly  re la ted  to  en o xaparin  
w as that d u e  to ce reb ra l haem orrhage .
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6. D isc u ss io n
6.1 Patient categories
T his stu d y  show s th a t L M W H s such as en o x ap arin  are b e in g  used  ro u tin e ly  by  
d iffe ren t sp ec ia litie s  for D V T  p ro p h y lax is  in  p a tien ts  u n d e rg o in g  a v a rie ty  o f  
su rg ical p ro ced u res  and  for those  req u iring  p ro lo n g ed  im m o b ilisa tio n , as w ell as 
for the trea tm en t o f  e s tab lish ed  D V T  and in the p rev en tio n  o f  u n stab le  ang ina  
and  m y o card ia l in farc tion .
E n o x ap arin  is used  ro u tin e ly  for D V T  p ro p h y lax is  in  m o st o rth o p aed ic  and 
g y n aeco lo g ica l su rg ica l p a tien ts , w h ile  in  v ascu la r su rg ery  pa tien ts , both  
u n frac tio n a ted  h ep a rin  and  en o xaparin  are u sed  for p ro phy lax is.
6.2 Patient Demographics
E ig h ty -fiv e  p e rcen t o f  gyn aeco lo g ica l pa tien ts  and 65%  o f  the v ascu la r patien ts  
seen  in  th is s tu d y  w ere  aged b e tw een  40 and 60 w ith  no ad d itiona l risk  factors 
and w ere  th ere fo re  at m o d era te  risk  for th ro m b o em b o lism  as d iscussed  under 
risk  ca teg o ries  u n d e r In troduction . T he rem ain in g  35%  o f  v a scu la r pa tien ts  had 
ad d itio n a l risk  fac to rs p lac in g  them  in to  the h ig h  risk  ca tegory , 18%  (n=3) w ere 
p rev io u s sm o k ers, 12%  (n=2) w ere  d iabetic  and 6%  (n=l) w as re trov ira l 
p ositive . F ifteen  p e r  cen t (n=2) o f  gyn aeco lo g ica l p a tien ts  h ad  a h is to ry  o f  
m alig n an cy  and  w ere  at h ig h  risk  for th ro m b o em b o lism . A ll m ed ica l patien ts  
w ere  at m o d era te  risk  o f  th rom boem bolism .
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6.3 Dose of therapy 
O rthopaedic surgery
A ll o rth o p aed ic  su rg ica l p a tien ts  rece ived  the  co rrec t p ro p h y la tic  dose , a 
te s tim o n y  to  b e tte r  co m p lian ce  o f  the sim p le  o n ce  d a ily  reg im en  o f  en o xaparin  
versus the 8-12 h o u rly  h ep arin  dosages. It w as en co u rag in g  to see that the  u se  o f  
en o x ap arin  as a th ro m b o p ro p h y lac tic  is ro u tin e  at the  Jo h an n esb u rg  G eneral 
H o sp ita l in acco rd an ce  w ith  its p roven  h ig h er e fficacy  than  h ep arin  in th is 
in d ic a tio n .19,23,25'
G enerally , 100%  o f  those  p a tien ts  rece iv in g  a fixed  dose  o f  4 0 m g  d a ily  for 
p ro p h y lax is  rece iv ed  th e ir  m ed ica tio n  from  the p h a rm acy  correctly . N o n ­
av a ilab ility  o f  d ru g s for tw o  p a tien ts  is a cause  for co n cern  and needs further 
in v estig a tio n  as to w h e th e r  a w ard  s tock  situ a tio n  o f  en o x ap arin  shou ld  not be 
co n sid ered , in th e  ev en t th a t the  p h a rm acy  is c losed .
T h e  ex cess iv e  p ro p h y lac tic  d o se  in  one  knee am p u ta tio n  p a tien t is n o t ideal as 
th is  m ay  lead  to  an  in crease  in ad v erse  even ts  su ch  as b leed ing .
T he d o s in g  o f  6 0 m g  tw ice  d a ily  in stead  o f  80m g tw ice  d a ily  u sed  in vascu la r 
pa tien ts  fo r th e  trea tm en t o f  c lau d ica tio n  req u ires  fu rth er in te rv en tio n  and 
ed u cation . T h ere  ap p ears  to  be  som e co n fu sio n  reg a rd in g  d o s in g  in  the 
trea tm en t o f  D V T  in  v a scu la r patien ts. A  case  has b een  rep o rted  in the  litera ture  
b y  R o d g e rs45 o f  an  in ap p ro p ria te  use  o f  en o x ap arin  to  trea t ven o u s 
th ro m b o em b o lism , w h e re  eno x ap rin  w as used  in  a  d o sag e  o f  3 0 m g  tw ice  daily  
for the  trea tm en t o f  D V T  w h ich  developed  four days a fte r  foo t su rg e ry  in a 48
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y ea r o ld  w o m an . A  few  days later, d y sp n o ea  occu rred  and  b ila te ra l p u lm o n ary  
em b o lism  w as d iag n o sed . T h is case illu stra tes that the ap p ro p ria te  dose  o f  
lm g /k g  tw ice  d a ily  sh o u ld  be  used  in the trea tm en t o f  D V T . T h is h igh ligh ts  
an o th er im p o rtan t p o in t and  that is s tric tly  speak ing , d o sag e  sh o u ld  be 
ca lcu la ted  on a m g /k g  d o sage  basis  and that the es tim a tio n  o f  g iv ing  80m g due 
to co n v en ien ce  o f  ad m in is tra tio n  o f  2 p re-filled  4 0 m g  sy rin g es be  re-co n sid ered  
w h en  the  p a tien t is c lea rly  be low  o r above average  adu lt w e ig h t i.e. less than 
50kg o r m o re  th an  80kg.
T he use o f  en o x ap arin  in the correc t dose  in the m o re  recen tly  app roved  
in d ica tio n  o f  trea tm en t o f  D V T  is encourag ing .
6.4 Duration of treatm ent
In su ffic ien t d u ra tio n  o f  trea tm en t in 2 o rth o p aed ic  p a tien ts  is a cause  for 
co n cern  and  in d ica tes  th a t th is  is an area  in w h ich  in v o lv em en t o f  the  c lin ical 
p h a rm ac is t can  im p ro v e  o u tco m e  in a patien t. T h e  d u ra tio n  o f  trea tm en t w ith  
en o x ap arin  in  v a scu la r  su rg ica l pa tien ts  o f  5 days, is s lig h tly  less th an  the  length 
o f  trea tm en t in  an o th e r  s tudy42 w h ich  in v estig a ted  low  m o lecu la r w e ig h t 
hep arin s  a fte r  fem o ro p o p litea l bypass g rafting , in w h ich  d u ra tio n  o f  trea tm en t 
w ith  th e  lo w  m o lecu la r w e ig h t heparin , d a ltep arin  w as  fo r 7 d ay s .T h is  m ay  be 
due to  red u ced  h o sp ita l stay  at the  Jo h an n esb u rg  G eneral H o sp ita l, d u e  to 
p ressu re  o f  b ed  space.
O f  th e  p a tien ts  u n d e rg o in g  trea tm en t o f  D V T , 2 o u t o f  5 p a tien ts  rece iv ed  the 
trea tm en t m ed ica tio n  fo r 5 to 10 days. O ne p a tien t rece iv ed  trea tm en t doses  for
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on ly  2 days and  the  o th er rece iv ed  trea tm en t doses for an in itia l 4 days fo llow ed 
b y  p ro p h y lac tic  doses  fo r an o ther 4 days. T he last p a tien t rece iv ed  trea tm en t for 
a lm ost five w eek s  due  to co n co m itan t p u lm o n ary  m alig n an cy . B y  con trast in a 
study  b y  H o w ard  43, 8 ou t o f  131 pa tien ts  rece iv ed  an tith ro m b o tic  th erap y  for a 
th ro m b o em b o lic  event. T w o  o f  these  pa tien ts  rece iv ed  4 to  5 days o f  low  
m o lecu la r w e ig h t h ep arin  o r un ffac tio n a ted  h ep arin  th e rap y  o v erlap p ed  w ith  
w arfarin . T w o p a tien ts  rece iv ed  low  m o lecu la r w e ig h t h ep arin  or u n frac tionated  
h ep arin  for a full 2 w eek s  w ith  no su bsequen t w arfa rin  therapy . In the rem ain ing  
four p a tien ts , w arfa rin  th erap y  w as e ither s ta rted  afte r m ore  than  2 days o f  
h ep arin  trea tm en t o r a fte r co m p le tio n  o f  at least 7 to 10 days o f  heparin . C learly  
the reco m m en d a tio n  in th is  s tu d y  co n d ucted  in the U n ited  S ta tes w as 4 to 5 days 
o f  low  m o lecu la r w e ig h t h ep a rin  or u n frac tio n a ted  h ep arin  ov erlap p ed  w ith  oral 
an tico ag u lan t, w arfa rin . H ere , in  S ou th  A frica , reco m m en d a tio n s  in the 
trea tm en t o f  D V T  are th a t a dose  o f  lm g /k g  shou ld  be  g iven  subcu tan eo u sly  
ev e ry  12 h o u rs  and  th a t o ra l an tico ag u lan t th e rap y  shou ld  be  in itia ted  w hen 
ap p ro p ria te  and  en o x ap arin  trea tm en t co n tin u ed  until a th e rap eu tic  an ticoagu lan t 
e ffec t has b e e n  ach iev ed  i.e. an In te rn a tio n a l N o rm alised  R a tio  (IN R ) =  2 to 3. 
E n o x ap arin  trea tm en t is u su a lly  p resc rib ed  for b e tw een  5 and  10 days.
T h e  p rac tice  o f  u s in g  en o x ap arin  as transien t o u tp a tien t an tico ag u lan t th erapy  
ov er w eek -en d s  n eed s  to b e  fu rther ex am in ed  to  es tab lish  i f  adequate  
an tico ag u la tio n  is ach iev ed  as w ell as ad m in is tra tio n  and  co m p lian ce  b y  the 
pa tien t. It is n o t g en e ra lly  reco m m en d ed  to  u se  h ep a rin  and  low  m o lecu la r 
w e ig h t h ep a rin s  in te rch an g eab ly . F u rth e r stud ies are w a rran ted  to  ex am in e  the 
ben efits  and  risk s  o f  u s in g  these  h eparins in te rch an g eab ly , as w e ll as a
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co n sen su s e s tab lish ed  as to how  the  p o ten cy  o f  h ep a rin  and  low  m o lecu la r 
w e ig h t h ep arin s  m ay  b e  o p tim ally  com pared .
T w o  m ix ed  m itra l v a lv e  pa tien ts  bo th  rece ived  an in itia l d o se  o f  4 0 m g  tw ice  
daily . It is no t c lea r w h y  80m g tw ice  d a ily  w as n o t in itia lly  p resc rib ed  espec ia lly  
as one  p a tien t w en t on  to  rece iv e  a m ain ten an ce  d o se  o f  4 0 m g  d a ily  for a further 
8 days and  th e  o ther, a d o se  o f  80m g in the  m o rn in g  and  4 0 m g  in the  even ing  
fo r a d u ra tio n  o f  17 days. It is th ere fo re  ap p aren t that in co m p lica ted  card iac  
p a tien ts  the  d o ses  p resc rib ed  in p rac tice  dev ia te  from  th o se  reco m m en d ed  and 
th is  m ay  be a ttr ib u ted  to co m p lica tio n s in the c lin ica l p ic tu re  o f  the  patient.
T he h ig h  d eg ree  o f  co m p lian ce  in d osage  and  d u ra tio n  o f  en o x ap arin  in the 
n ew ly  reg is te red  in d ica tio n  o f  the p rev en tio n  o f  ischaem ic  co m p lica tio n s o f  
un stab le  an g in a  o r no n  - Q -w ave  m y o card ia l in fa rc tio n  are encourag ing . 
P h y sic ian s in the  m ed ica l w ards have  therefo re  no t h es ita ted  to p u t the  resu lts  o f  
the E S S E N C E 44 tria l into p ractice . T he E S S E N C E  tria l w as a do u b le  b lind , 
p lacebo  co n tro lled  tria l carried  out in 3171 p a tien ts  w ith  an g in a  at rest or non -  
Q -w ave  m y o card ia l in farc tion . T his trial show ed  that an tith ro m b o tic  therapy  
w ith  en o x ap arin  p lu s  asp irin  w as m ore effec tive  th an  u n frac tio n a ted  heparin  
p lus asp irin  in  red u c in g  the  in c idence  o f  ischaem ic  even ts  in p a tien ts  w ith  
un stab le  an g in a  o r n o n -Q -w av e  m yocard ia l in farction .
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6.5 Pre-operative dosing interval
T h irty -fiv e  p e rcen t o f  o rth o p aed ic  p a tien ts  and 38%  o f  g y n aeco lo g ica l su rg ical 
pa tien ts  d id  no t rece iv e  p re-o p e ra tiv e  doses. In co m p ariso n  R o ch a t36 found that 
at K ing  E d w ard  H o sp ita l, 65%  o f  gynaeco lo g ica l and  89%  o f  su rg ica l pa tien ts  
rece ived  no p re -o p e ra tiv e  dose  and w hen  it w as g iven , it w as g iv en  late. In 
v a scu la r su rg e ry  no  p a tien ts  rece iv ed  any  p re -o p e ra tiv e  d o ses  in  an  e ffo rt to 
m in im ise  ad v erse  e ffec ts  o f  b leed ing .
T he av erag e  p re -o p e ra tiv e  d o sin g  in te rval in th is  s tu d y  w as 13,4 hours. T his 
d o sin g  in te rval fa lls  w ith in  the  s tipu la ted  c rite ria  o f  12 h o u rs  p r io r  to  surgery , 
peak  ac tiv ity  o ccu rrin g  3 ho u rs  afte r ad m in istra tion . T h ere fo re  i f  th e  p re ­
o p era tiv e  d o se  is g iven  too  late, the p a tien t co u ld  b e  at increased  risk  o f  in tra ­
o p era tiv e  h aem o rrh ag e .
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6.6 Post-operative dosing interval
T h e  p o s t-o p e ra tiv e  tim in g  o f  en o xaparin  is c lin ica lly  im portan t. T h o se  pa tien ts  
w ho rece iv ed  th e ir  p o s t-o p e ra tiv e  en o x ap arin  dose  less th an  13 ho u rs  after 
su rgery , had  in creased  co m p lica tions. Shaieb  et a l.33 also  found that pa tien ts  
rece iv in g  the firs t dose  o f  en o x ap arin  10 hours o r m ore  p o s t-o p e ra tiv e ly  had 
s ig n ifican tly  few er co m p lica tio n s. P a tien ts  th a t had  co m p lica tio n s  rece ived  the 
first dose  at a  m ean  o f  6 hours po st-o p era tiv e ly . T h e  la te r d o s in g  o f  en o x aparin  
a llo w ed  h aem o stas is  to  b e  estab lish ed  and  w as found  to d ecrease  co m p lica tions. 
L e izo ro v icz  et a l.34 h av e  a lso  rep o rted  a reduced  in c id en ce  o f  m ajo r b leed in g  i f  
the  firs t in jec tio n  is g iven  a long  tim e b efo re  o r a fte r  th e  o p e ra tio n  and 
reco m m en d ed  a larg e  scale  tria l to  an sw er the q u es tio n  o f  w h e th e r g iv ing  the 
first in jec tio n  12 o r 24  ho u rs  b efo re  su rgery  or 12 hours afte r su rg ery  is the 
b e tte r a lte rna tive .
C o n cern in g  the m an ag em en t o f  an tico ag u la tio n  b efo re  and afte r e lective  
su rgery , K earon  and H irsch 40 c learly  reco m m en d  that w ith  h ep arin  therapy , 12 
hours sh o u ld  be  a llow ed  afte r m ajo r su rg ery  b efo re  res ta rtin g  o f  therapy , and i f  
there  is an y  ev id en ce  o f  b leed ing , h eparin  th e rap y  shou ld  be  de lay ed  even  
longer.
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6.7 C oncurrent adm inistration with and timing of dose of enoxaparin in 
relation to epidural
T here  is an in c rease  in co m p lica tio n s w ith  the co n cu rren t ad m in is tra tio n  o f  
en o x ap arin  and  an ep idu ra l, the rate  o f  w h ich  is increased  fu rth er i f  the tim e 
d iffe ren ce  b e tw een  the  end  o f  the ep idural b lo ck  and  the first dose  o f  enoxaparin  
is less th an  12 hours.
In th is  s tu d y  5 p a tien ts  rece iv ed  ep idural an aesth esia  w h ile  an tico ag u la ted  w ith  
eno x ap arin . T w o  o f  th ese  pa tien ts  rece ived  th e ir p o s t-o p e ra tiv e  en o x ap arin  
doses w ith in  10 h o u rs  o f  the end  o f  the ep idu ra l b lo ck  and  b o th  o f  these  patien ts  
had  co m p lica tio n s.
T he U n ited  S ta tes F ood  and D rug  A d m in is tra tio n  (F D A ) has w arn ed  c lin ic ians 
abou t the  p o ten tia l co m p lica tio n s o f  pe rm an en t p a ra ly sis  i f  b leed in g  w ith in  the 
spinal co lu m n  occu rs from  the use o f  L M W H s. B leed in g  o r h aem ato m as w ith in  
the sp ina l co lu m n  m ay  resu lt w hen  the heparin  p ro d u c t is used  co n cu rren tly  
w ith  sp inal o r ep id u ra l an aesth esia  o r spinal p u n c tu re . T he risk  for the 
co m p lica tio n  in creases  w ith  1) catheters p laced  in the sp ina l canal to ad m in iste r 
p a in  m ed ica tio n , 2) b y  the  use o f  o ther drugs a ffec tin g  b lo o d  c lo ttin g  
m ech an ism , such  as no n -ste ro id a l an ti-in flam m ato ry  d ru g s, p la te le t inh ib ito rs, 
or o th er an tico ag u lan ts , o r by  3) traum atic  or rep ea ted  ep idu ra l o r spinal 
punctu re . M o re  th an  30 repo rts  have b een  su b m itted  to th e  F D A  d escrib in g  
n eu ro log ic  in ju ry , inc lu d in g  long-te rm  or p e rm an en t p a ra ly sis , w ith  the
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co n cu rren t u se  o f  en o x ap arin  and  sp in a l/ep id u ra l an esth es ia  o r spinal punctu re . 
M ost o f  the  p a tien ts  w ere  e ld erly  w o m en  u n d erg o in g  o rth o p aed ic  surgery . 
C lin ic ian s sh o u ld  fu lly  co n sid er the po ten tia l b en e fit v e rsu s  risk  b efo re  
n eu rax ia l in te rv en tio n  in  pa tien ts  an tico ag u la ted  o r in th o se  p a tien ts  schedu led  
for an tico ag u la tio n  w ith  enoxaparin .
6.8 Concom itant therapy
T he lack  o f  a s ig n ifican t in te rac tion  w ith  co n co m itan t N S  A ID  th erap y  m ay  have 
been  due  to the  p a tien t n u m b ers  be ing  sm all, so that a s ig n ifican t d iffe rence  
co u ld  n o t b e  de tec ted . R o b in so n  et al. 35 found a s ig n ifican tly  increased  
p erio p e ra tiv e  b lo o d  loss and  tran sfu sio n  req u irem en t in e lec tiv e  hip arth rop lasty  
p a tien ts  rece iv in g  n o n -ste ro id a l an ti-in flam m ato ry  d rugs in  the p re-o p era tiv e  
p e rio d  w h en  co m p ared  w ith  a con tro l g roup  rece iv in g  o th er fo rm s o f  ana lg esia  
fo r th e ir  o steo a rth ritis . T h e  ran g e  o f  in creased  b lo o d  loss v aried  from  1,57 to
2 .08 tim es the  b lo o d  loss in the con tro l g roup  and w as seen  w hen  the opera tion  
w as ca rried  o u t u n d e r sp inal as w ell as general an aesthesia . T he d ed u c tio n  then 
w o u ld  b e , th a t an aw aren ess  o f  increased  tran sfu s io n  req u irem en ts  as w ell as for 
o th er p o ten tia l side  e ffec ts  such as an in creased  risk  o f  b leed in g  w o u ld  be 
req u irem en ts  w h en  p a tien ts  rece iv in g  n o n -ste ro id a l an ti- in flam m ato ry  d rugs are 
an tico ag u la ted  w ith  enoxaparin .
C o n ce rn in g  o v erlap  o f  w arfa rin  and  enoxaparin , H o w ard  et a l.43 found 
co n sid e rab le  v a ria tio n s  in the  conversion  to chron ic  w arfa rin  th e rap y  for
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trea tm en t pa tien ts . A m erican  C ollege o f  C hest P h y sic ian s  (A C C P ) gu idelines 
reco m m en d  s im u ltan eo u s  in itia tion  o f  w arfarin  w ith  u n frac tio n a ted  h ep arin  or 
low  m o lecu la r w e ig h t h ep arin  for at least 4 to 5 days. A fter the IN R  is 
therap eu tic  fo r 2 co n secu tiv e  days, the  h ep arin  can be  d isco n tin u ed . T his 
m eth o d  o f  in itia tin g  o ral an tico ag u la tio n  has severa l p o ten tia l adv an tag es, 
in c lu d in g  m in im is in g  the  leng th  o f  h ep arin  th e rap y  and  th e  risk  o f  d rug -induced  
th ro m b o cy to p en ia  and  red u c in g  the leng th  o f  h o sp itilisa tio n .
T w elv e  p e rcen t o f  p a tien ts  w ere  co n cu rren tly  rece iv in g  asp irin  and  enoxaparin . 
In co m p ariso n , H o w ard  et a l.43 found that 30%  o f  p a tien ts  w ere  rece iv in g  
co n cu rren t an tip la te le t o r oral an tico ag u lan t th erap y , p lac in g  th em  at h igher risk 
for h aem o rrh ag ic  com p lica tio n s.
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6.9 Post-operative haemoglobin value decrease
T he m ean  p o s t-o p e ra tiv e  h aem o g lo b in  d ecrease  w as 4 .07  ± 1 .1 2  g/dl in 
o rth o p aed ic  p a tien ts , 2 .97  ±  0.31 g/dl in vascu la r p a tien ts  and 4 .53 ±  1.56 g/dl in 
m ed ical patien ts.
In the re fe ren ced  case  co n tro l s tudy  o f  156 pa tien ts , S haieb  et a l.33 found a p o st­
op era tiv e  h aem ato c rit decrease  that w as s ig n ifican tly  g rea ter for the enoxaparin  
g ro u p (1 7 ,9 %  vs 14,1%  p= 0 .0 0 2 ) for all p ro ced u res  as w ell as fo r the  p rim ary  
unila te ra l p ro ced u res  (17,5  %  vs 12,7%  p= 0 .0004). A n aw aren ess  o f  th is 
p o ten tia l d ecrease  in h aem o g lo b in  by  c lin ic ians w o u ld  be  reco m m en d ed  as the 
n ecessa ry  step s  and  p recau tio n s  for b lood  tran sfu sio n s can  be  taken.
6.10 Throm bocytopenia
T he in c id en ce  o f  th ro m b o cy to p en ia  found  in  th is  s tu d y  w as 4% . In co m parison , 
in a s im ila r 3 m o n th  s tudy  ca rried  o u t b y  H o w ard  et a l,43 p resc rib in g  p a tte rns 
and o u tco m es asso c ia ted  w ith  the  use  o f  bo th  low  m o lecu la r w e ig h t h eparin  and 
u n frac tio n a ted  h ep a rin  fo r p ro p h y lax is  o r trea tm en t o f  th ro m b o em b o lism  w ere 
in v estig a ted  in  131 p a tien ts . It w as found  that 2 cases o f  th ro m b o cy to p en ia  
d ev e lo p ed  in p a tien ts  rece iv in g  en o x aparin  i.e. an in c id en ce  o f  1,5% .
S am am a et a l.37 h av e  rep o rted  a ra te  o f  2.2 %  (re la ted  &  u n re la ted ) o f  
th ro m b o cy to p en ia  in 360  acu te ly  ill m ed ical p a tien ts  on  4 0 m g  da ily  
p ro p h y lac tic  d o se  o f  enoxaparin . T he p ercen tag es o b ta in ed  in  th is  s tu d y  m ay  be
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ex ag g era ted  due  to  sm all p a tien t num bers. N ev e rth e le ss  th ey  are in d ica tiv e  that 
the  m o n ito rin g  o f  p la te le t coun ts is n ecessa ry  d u rin g  en o x ap arin  usage.
T he cu rren t p ack ag e  in se rt fo r en o x ap arin  does q u o te  th a t tran s ien t 
a sy m p to m atic  th ro m b o cy to p en ia  has been  rep o rted  d u rin g  th e  firs t days o f  
th e rap y .30 H o w ev er, h ep a rin  induced  th ro m b o cy to p en ia , a sso c ia ted  th rom bo tic  
even ts  and  h ep a rin -d ep en d en t IgG  an tibod ies are  m o re  co m m o n  in  pa tien ts  
trea ted  w ith  u n frac tio n a ted  hep arin , th an  in th o se  trea ted  w ith  L M W H .39 R are 
cases o f  an tib o d y -m ed ia ted  h ep a rin -in d u ced  th ro m b o cy to p en ia  have  a lso  been  
rep o rted  w ith  en o x ap arin . H ep arin  in duced  th ro m b o cy to p en ia  is d e fin ed  as a 
decrease  in  th e  p la te le t co u n t to b e lo w  1 5 0 ,000 /m m 3 afte r 5 days o f  trea tm en t
TO
w ith  the  s tu d y  d ru g  p lu s  a p o sitiv e  tes t fo r h ep a rin  d ep en d en t IgG  an tibod ies.
T h e  m an u fa c tu re r  th e re fo re  reco m m en d s th at p la te le t co u n ts  b e  m easu red  before  
the in itia tio n  o f  th e rap y  w ith  en o x ap arin  an d tthen  reg u la rly  th e rea fte r  du ring  
trea tm en t. In  p rac tice , i f  a co n firm ed  sig n ifican t d ec rease  o f  th e  p la te le t coun t is 
o b serv ed  (30  to 50 %  o f  th e  in itia l value), en o x ap arin  trea tm en t m u st be  
im m ed ia te ly  d isco n tin u ed  and the  pa tien ts  sw itch ed  to an o th e r therapy .
6.11 M ajor Complications/Haem orrhages.
T he ra te  o f  m a jo r  h aem o rrh ag e  in th is s tu d y  w as 2 /76  (2 ,6% ). In  co m p ariso n  as 
a re fe ren ce  in  a case  co n tro l s tu d y  o f  156 pa tien ts , th e  ra te  o f  m ajo r 
co m p lica tio n  ra te  w as  3 ,3%  in the en o x aparin  group . T h ese  in c lu d ed  one  case  o f  
ep idu ra l h a e m a to m a  req u irin g  su rg ical d eco m p ress io n  in  the  en o x ap arin  group , 
as w ell as fou r m a jo r  h aem o rrh ag es w ith  one also  a sso c ia ted  w ith  
th ro m b o cy to p en ia .
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7. Conclusion and recommendations
This study shows that although enoxaparin is a safe and reliable medication in 
the prevention o f DVT, it is not without hazards and certain precautions should 
be observed in its use. Familiarity with dosages is higher in medical and 
orthopaedic patients than in vascular patients.
Although most prescribers were familiar with dosages to be used, in at least 2 
patients, the dose prescribed by the intern or houseman had to be corrected by 
the consultant or registrar. This indicates that further education and detailing is 
required in this area. Therapy was usually prescribed for the correct duration of 
time. Dose modifications in special populations such as renal failure as well as 
obese or underweight patients is important. It may be an advantage to obtain 
baseline patient weights before start o f therapy, so that should dosages need to 
be adjusted according to a change in circumstances, this can be done.
The omission o f pre-operative doses o f enoxaparin in 35% o f orthopaedic and 
38% o f gynaecological patients requires further investigation. It was 
encouraging to find that the pre-operative dosing interval o f at least 12 hours 
before surgery was observed in all patients. The fact that those orthopaedic 
patients who received their post-operative enoxaparin on the same day as their 
surgery displayed an increase in complications, illustrates that post-operative 
doses o f enoxaparin should be delayed for at least 24 hours post-operatively. 
The need for epidural anesthesia with concurrent enoxaparin usage needs to be 
questioned. If  it cannot be avoided, the lowest effective dose o f enoxaparin
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should be used and enoxaparin use should be interrupted at least 12 hours before 
and after neuraxial block.
Although concomitant administration o f non-steroidal anti-inflammatory drugs 
did not appear to cause a direct increase in the rate of complications, an 
awareness o f the possibility o f increased blood loss and increased transfusion 
requirements in these patients is advised. Concurrent administration of oral 
contraceptives and hormone replacement therapy did not seem to be an issue 
with the gynaecological patients.
To minimise injection site reactions and increase convenience o f administration, 
it is recommended that the 80mg prefilled syringe be made available to those 
wards such as the medical wards, where more patients are being prescribed the 
treatment dosage. By using the 80mg pre-filled syringe, the patient on an 80mg 
twice daily dosage receives two needle pricks per day as opposed to four 
needlepricks per day with the 40mg syringe. This would also save time of the 
nursing personnel, who would only have to administer one injection as opposed 
to two injections.
Monitoring o f platelet counts is also recommended during enoxaparin therapy. 
Although elevated protein-C levels were found in 2 patients, routine monitoring 
o f inherited thrombophilias was not performed and may be warranted to identify 
predisposed individuals, so that the necessary precautions can be taken to 
minimise complications.
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Last, but not least, prescribers should remain vigilant concerning the possibility 
of bleeding, decreases in haemoglobin and possibly an increased need for 
transfusions in patients who have been on enoxaparin, and not be lulled into a 
false sense o f security that “enoxaparin causes less bleeding than heparin.”
This study indicates that there are many areas in which the pharmacist can 
become actively involved and by making available his pharmaceutical expertise 
and knowledge, contribute towards improving outcomes o f therapy in patients.
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A ppend ix  A : D R U G  U S E  E V A L U A T IO N  O F  E N O X A P A R IN
1. P A T IE N T  D E M O G R A P H IC S
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A p p e n d i x  B
P atien t In form ation  & C onsent F orm
You have been admitted to hospital in order to undergo an operative procedure following which 
you will undergo a period of recovery. Because recovery involves bed rest, this means you will 
not be able to walk very frequently and will generally be confined to lie in bed. This type of 
immobilisation, i.e. not being able to move around can sometimes cause clots to form in the 
blood. To prevent any clots from forming in your blood your surgeon/doctor will prescribe a 
medication called Clexane® which you will receive as a daily injection.
I am presently conducting research to evaluate how this medication is being prescribed in 
patients such as yourself and am requesting you to consider participation in my study. The aim 
of the study is to evaluate how Clexane is being used, whether is interferes with any other 
medication and in addition how well it is tolerated in patients.This research has been approved 
by the Postgraduate and Ethics committees of the University of Witwatersrand. If you 
choose to participate in this research study by signing the attached consent form, you will be 
among 100 other similar patients expected to enter this study from this ward of the 
Johannesburg Hospital. The study will begin from the time you receive your first dose of 
Clexane® (enoxaparin) until the last dose is given in hospital. I will need to consult your 
bedletter and medical records to monitor how the drug is being given.
There are no direct benefits from your participation in this study, but future patients may benefit 
from the research data collected as a result of your participation. Participation in this study is 
voluntary. By declining to participate in this research study, you will not be giving up any of 
your rights, or incur any penalty or loss of benefit to which you are otherwise entitled. Your 
identity and the data collected as part of this research will be kept strictly confidential. You may 
also withdraw from this study at any time, should you wish to do so.
If you have any questions about the study, you may contact me, Devi Nagar at 797 1255 / 082 
5519 807.
I, the undersigned, having read and understood the above patient information, hereby give my 
consent to participate in this study.
Patient Nam e:....................................................................
Patient Signature :...........................................................Date
Researcher N am e:...................................................................
Researcher Signature:...................................................Date:
Witness N am e:....................................................................
Witness Signature : ....................................................... Date:
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Appendix C : Summary of orthopaedic patient data
Patnt Gend Age Indication Dose Dura Admin Pre-op int Post-op int Epid int Concur Rx Inj rxn Base Hb Hb on Rx Hb diff P-op Trans Base Pit Pit on Rx Pit diff Hemorrhage Outcome
001 M 54 LTHR 40mg od 9 12.5 25 153 10.7 4.6 n/a
002 M 49 LTHR 40mg od 14 11.5 22 Hemat 0
003 F 56 THR 40mg od 8 3 days om 13.5 69 7 14.3 10.1 4.2
004 M 74 THR 40mg od 4 12 9 8.6 5.2 3.4 Major/H inst Ren failure/Death
005 F 39 R THR 40mg od 9 Not given 23.5 12 12 0 2U blood
006 M 69 LTHR 40mg od 9 13 47 12.7 10.6 2.1 P-op urinary reten
007 F 70 LTHR 40mg od 13 Not given 20 13 9.5 3.5 2U blood
008 F 50 THR 40mg od 10 Not given 23 Pir.Meth, M 0
009 F 33 THR 40mg od 7 16.5 21.5 10.4 9.3 1.1 411
010 M 70 THR 40mg od 6 23.5 16.7 12.4 4.3 241
011 F 61 THR 40mg od 10 1 day om Not given 12 9 11.5 10.9 0.6 3U blood
012 F 51 THR 40mg od N/A 11 23.5 Naprosyn 0
013 M 69 THR 40mg od 12 Not given 23 23 0 0.5IH+2U B
014 F 57 TKR 40mg od 12 13 49 15.8
015 F 83 TKR 40mg od 11 Not given 23.5 15.3 105 4.8 Whole blood
016 F 74 TKR 40mg od 13 11 23 11.1 8.9 2 2
017 F 84 TKR 40mg od 10 17 21 9.9 11.4 -1.5 271
018 F 68 ACETREV 40mg od 7 16 19 15.7 10.1 5.6 0.5IH +2Ub
019 F 24 STEIMAN 40mg od 8 Not given 43 0 239 Minor/pinsite
020 M 84 ARTHROP 40mg od 36 13 23 Warfarin 13.9 9.8 4.1 298 396 -98
9.25 13.36364 27.02778
11.5
A p p e n d i x  D :  S u m m a r y  o f  v a s c u l a r  p a t i e n t  d a t a
P a tn t G end  A g e  In d ica tion In itia l dose D u ra  M a in td o s e  D ura  C o n c u r R x Inj rxn B ase  Hb H b on R x Hb d iff B ase  P it P it on Rx P it d if f  O u tco m e
V01 M 58 F e m -X o ve r/C la u d 6 0 m g ?  bd 3 4 0 m g  bd 1 13.4 14 -0 .6 208 143 65
V 0 2 M 72 A n g io p la s ty 4 0 m g  od 6 A s p  150od 15.3 13.4 1.9 205 151 54
V 0 3 M 55 A n e u ry s m /D V T 80m g bd 12 B ru is ing 15.6 15.4 198 197 1
V 0 4 M 61 F em ora l g ra ft 4 0 m g o d 3 12.3 13.3 200 252 -5 2  T ra n s ie n t p ro p h y
V 0 5 F 37  A K A 4 0 m g  od 29 123 930 -8 0 7  P t d ie d /s e p tic e m ia
V 0 6 M 50 Fem  - P op  B yp a ss  4 0 m g  od 5 8 0 m g  bd 6 0
V 0 7 M 6 9  A A  a n e u rysm 4 0 m g  od 6 9.1 12.6 538 4 0 3 135
V 0 8 M D V T 8 0 m g  bd 2 0
V 0 9 F 4 9  C e llu lit is 4 0 m g  od 3 0
V 1 0 F 4 3  A V  F is t re p a ir 4 0 m g  od 7 14.8 14 122 165 -43
V 11 F 6 5  C la u d ica tio n 6 0 m g ?  bd 4 203 184 19
V 1 2 M 5 6  D V T 80m g bd 10 0
V 1 3 F 41 D V T 80m g bd 7 5 .3 9 .9 382 481 -99
V 1 4 M 7 0  A K A 6 0 m g  od 0
V 1 5 M 6 6  A K A 4 0 m g  od 3 12.5 9.8 361 276 8 5  P t d ied  11 /5
V 1 6 F 6 3  B K A /D V T 80m g bd 10 B ru is ing 10.5 7 .2 4 4 4 171 273
V 1 7 Bil B K A 4 0 m g  od 14 9 .8 6 .9 122 52 70
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Appendix E:Summary of gynaecological patient data
P atn t G en d  A ge Indication D ose Duration Adm in
G 01 F 32  TAH 40m g  od 2
G 0 2 F 54  O ophorectom y 40m god P re-op  only
G 0 3 F 4 8  T A H  & B S O 40m g  od P re-op  only
G 0 4 F 4 8  T A H  & B S O 40m g  od P re-op  only
G 0 5 F 59  TA H 40m g  od P re-op  only
G 0 6 F 52  TA H 40m g  od P re-op  only
G 0 7 F 6 5  TA H  & B S O 40m g  od P re-op  only
G 0 8 F 51 V ulvectom y 40m g  od P re-op  only
G 0 9 F 6 2  TAH 40m god P re-op  only
G 1 0 F 6 2  V au lt suspension 40m god P re-op  only
G 11 F 59  C A  ovary/thr limb 80m g bd 2
G 1 2 F 71 C A  ovary 40m g  od 11
G 1 3 F 38  TAH 8 0 M G  BD 2
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P re-op  int Post-op int Epid int 
13 35
11 
10 
12
15 
17
16  
13.5
C on cu r Rx  
Triphasil
A p p e n d i x  F :  S u m m a r y  o f  m e d i c a l  p a t i e n t  d a t a
Patnt Gend Age Indication Initial dose Dura Maint dose Dura Admin Concur Rx Inj rxn Base h Fib on Rx Hb diff Base Pit Pit on Rx Pit d iff Thrombo Flemorrhage Outcome
M01 M 52 Ml 80mg bd 6 arm? Y 16.1 16.7 -0.6 253 212 41
M02 M 68 CMO 40mg od 6 Asp150 od 0 0
M03 M 65 NQMI 40mg bd(lost limb) 8 Y 13.2 13.4 -0.2 332 339 -7
M04 M 67 Ml 80mg bd 5 Asp 150od 0 0
M05 F 62 UA 80mg bd 2 0 0
M06 M 55 AF/M I 80mg bd 20 0 234 57 177 Cytopenia Min angio site
M07 M 34 RHD 40mg od 4 0 0 Occult blood
M08 M 72 Heartblock/CABG 40mg od 17 Y 9.8 9.6 0.2 146 41 105 Cytopenia Died- subs visit
M09 F 52 Pulm oedema/HT 80mg bd 3 40mg od 3 0 0
M10 M 28 O rganoP04 pois 40mg od 6 9.4 10.1 -0.7 575 478 97
M11 F 19 MVR 40mg bd 23 80om&40 on 17 10 7.1 2.9 310 92 218 Cytopenia
M12 F 65 CP&cellu 40mgod(125kg?) 7 8.6 9.7 -1.1 191 236 -45 Died - subs visit
M13 M 73 DJ stent 40mg od 4 0 218 165 53 Lung adenoCA
M14 F n/a MMVD 40mg bd 5 40mg od 8 9.1 9.7 -0.6 399 176 223
M15 M 36 Myocarditis 40mg od 11 14.5 8.5 6 340 157 183
M16 M 58 CCF 7 0 0
M17 M 81 Ml 80mg bd 5 40mg od 3 11.2 9.9 1.3 171 116 55 Died-not related
M18 M 37 Lung reduct 40mg od 10 Self 15.7 11 4.7 338 702 -364 Cytosis
M19 M 44 Ml 80mg bd 3 40mg od 4 Asp 150od
M20 M 50 Ml 80mg bd 7 Asp150 od 15 9 15 295 277
M21 F 73 UA 80mg bd 7 40mg od 11 Self Asp150 od Min- inj site Well
M22 F 51 UA 80mg bd 3.5 Asp150od Y & burning Bruising Well
M23 M 56 Ml 80mg bd 2.5 Asp150od Pt RHTed
M24 F 56 PE 80mg bd 1.5 Hep/W arf Cerebral Hem
M25 F 75 D V T  1C A  lung (40mg)80mg bd 34 Pirox/W arf Y 11.9 11.5 310 268 Bruising Correct overlap
M26 F 54 DVT 80mgbd 4 40mg od 4 Min- inj site Dvt resolved
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